

# Unraveling the Link between Periodontitis and Inflammatory Bowel Disease: Challenges and Outlook

Himanshi Tanwar<sup>1, #</sup>, Jeba Mercy Gnanasekaran<sup>1, #</sup>, Devon Allison<sup>1</sup>, Ling-shiang Chuang<sup>2</sup>,  
Xuesong He<sup>3</sup>, Mario Aimetti<sup>4</sup>, Giacomo Baima<sup>4</sup>, Massimo Costalonga<sup>5</sup>, Raymond K. Cross<sup>6</sup>,  
Cynthia Sears<sup>7</sup>, Saurabh Mehandru<sup>2</sup>, Judy Cho<sup>2</sup>, Jean-Frederic Colombel<sup>2</sup>, Jean-Pierre Raufman<sup>6</sup>,  
Vivek Thumbigere-Math<sup>1, 8, \*</sup>

## Affiliations:

<sup>1</sup> Division of Periodontology, University of Maryland School of Dentistry, Baltimore, MD, USA

<sup>2</sup> Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>3</sup> Department of Microbiology, The Forsyth Institute, Cambridge, MA, USA

<sup>4</sup> Department of Surgical Sciences, C.I.R. Dental School, University of Turin, Turin, Italy.

<sup>5</sup> Department of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, USA

<sup>6</sup> Division of Gastroenterology & Hepatology, University of Maryland School of Medicine, Baltimore, MD, USA

<sup>7</sup> Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA

<sup>8</sup> National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA

\* To whom correspondence should be addressed: [vthumbigere@umaryland.edu](mailto:vthumbigere@umaryland.edu)

# These authors contributed equally to the study

**Short Title:** Periodontitis and Inflammatory Bowel Disease Interconnection

**Key Words:** Periodontitis, Inflammatory bowel disease (IBD), Oral bacteria, Oral-gut axis, Gum-gut axis, Immune response, Dysbiosis, Ulcerative colitis, Crohn's disease.

Total Words: 7,016

Figures - 3

Tables – 2

Reference – 341

## **Abstract**

Periodontitis and Inflammatory Bowel Disease (IBD) are chronic inflammatory conditions, characterized by microbial dysbiosis and hyper-immunoinflammatory responses. Growing evidence suggest an interconnection between periodontitis and IBD, implying a shift from the traditional concept of independent diseases to a complex, reciprocal cycle. This review outlines the evidence supporting an "Oral-Gut" axis, marked by a higher prevalence of periodontitis in IBD patients and vice versa. The specific mechanisms linking periodontitis and IBD remain to be fully elucidated, but emerging evidence points to the ectopic colonization of the gut by oral bacteria, which promote intestinal inflammation by activating host immune responses. This review presents an in-depth examination of the interconnection between periodontitis and IBD, highlighting the shared microbiological and immunological pathways, and proposing a "multi-hit" hypothesis in the pathogenesis of periodontitis-mediated intestinal inflammation. Furthermore, the review underscores the critical need for a collaborative approach between dentists and gastroenterologists to provide holistic oral-systemic healthcare.

## **Introduction**

Oral pathologies can profoundly impact general health; however, oral health and general health are often incorrectly perceived as separate entities<sup>1,2</sup>. Over the past four decades, several studies have highlighted the connection between the oral cavity and the rest of the body, linking more than 50 systemic conditions, including inflammatory bowel diseases (IBD), to gingival and periodontal inflammation<sup>1-7</sup>. A bidirectional relationship exists between periodontitis and IBD, where chronic inflammation in either the oral cavity or intestinal tissues can influence each other. Microbial and inflammatory changes originating in the oral cavity can potentially initiate or exacerbate IBD. The growing body of literature associating periodontitis with gastrointestinal (GI) disorders such as IBD and colorectal cancer has seen a remarkable surge in recent years, with over 100 relevant articles published since 2020. This review aims to augment current knowledge by providing an in-depth analysis of the underlying mechanisms contributing to the bidirectional relationship between periodontitis and IBD. We utilize the "oral-gut axis" as a framework to investigate the reciprocal relationship between the periodontium and the GI tract. This narrative review encapsulates historical studies on oral manifestations in IBD, and explores recent advances, current knowledge gaps, and potential future directions. Furthermore, the review underscores the critical need for a collaborative approach between dentists, gastroenterologists, immunologists, and infectious disease experts/microbiologists to provide holistic oral-systemic healthcare.

## **Periodontitis**

Periodontitis is a chronic inflammatory disease that affects the periodontium, encompassing tooth-supporting structures such as the gingiva, alveolar bone, and periodontal ligament<sup>7-10</sup>. It is ranked as the 11th most prevalent condition worldwide, affecting approximately

50% of adults over 30 years of age and about 70.1% of adults over 65 years of age<sup>11-15</sup>. The hallmark symptoms of periodontitis are gingival inflammation, gingival recession, halitosis, deep periodontal pockets, clinical attachment loss, and tooth mobility<sup>7-10</sup>. If left untreated, periodontitis results in tooth loss, and is the leading cause of tooth loss in adults worldwide<sup>10,11,16,17</sup>.

Periodontitis is primarily initiated by the accumulation of bacterial plaque on tooth surfaces or within the gingival sulcus, which subsequently triggers an inflammatory response in the periodontium<sup>9,18</sup>. The host's hyper-immunoinflammatory response, in turn, leads to the destruction of tooth-supporting structures<sup>19-21</sup>. The bacterial plaque/calculus associated with the initiation of periodontitis specifically contains bacteria, such as *Porphyromonas gingivalis*, *Tannerella forsythia*, *Treponema denticola*, *Aggregatibacter actinomycetemcomitans*, *Prevotella intermedia*, *Fusobacterium nucleatum*, and *Campylobacter rectus*<sup>18-20,22-26</sup>. Periodontitis is a polymicrobial disease primarily driven by bacteria; however, fungi, protozoa, and viruses might also contribute to its pathogenesis<sup>9,27,28</sup>.

Several risk factors have been associated with periodontitis, including poor oral hygiene, smoking, diabetes, advanced age, genetics, and certain medications<sup>7,29-31</sup>. The prognosis depends on disease severity, patient compliance with treatment, and control of risk factors<sup>32</sup>. Through dissemination of oral pathogens and promotion of low-grade systemic inflammation, periodontitis may contribute to other systemic diseases such as IBD, cardiovascular disease, diabetes, and pre-term birth<sup>33-38</sup>. Periodontitis management focuses on infection control, reduction of inflammation, and preservation of tooth-supporting structures. Treatment strategy includes a sequential approach - (a) Control of local and systemic risk factors such as smoking and uncontrolled diabetes mellitus;

(b) Non-surgical therapy: scaling and root planing to remove bacterial plaque and calculus; (c) Medications: antimicrobial therapies, including local or systemic antibiotics, antiseptics, and host-modulating agents to manage bacterial infection; and (d) Surgical treatments: flap surgery, bone or soft tissue grafts, and guided tissue regeneration to manage advanced cases of periodontitis<sup>39</sup>.

## **Inflammatory Bowel Disease**

IBD encompasses a group of chronic, idiopathic, and recurring inflammatory disorders affecting the GI tract. The two primary forms of IBD are Crohn's disease (CD) and ulcerative colitis (UC)<sup>40-42</sup>. The clinical manifestations of IBD vary depending on the location and severity of inflammation within the GI tract. CD is characterized by patchy inflammation that can affect the full thickness of the bowel wall throughout the small and large intestines<sup>42-45</sup>. There may be areas of healthy tissue between inflamed sections (skip lesions). In contrast, UC presents with continuous, uniform inflammation limited to the mucosal layer, extending from the rectum throughout the colon<sup>42-46</sup>. Common symptoms include abdominal pain, cramping, persistent diarrhea, nausea, vomiting, weight loss, fatigue, and fever<sup>40-42,47</sup>. UC more likely causes bloody diarrhea, urgency to defecate, and tenesmus<sup>46-49</sup>. Approximately 25-40% of UC and CD patients may exhibit extraintestinal manifestations such as arthritis, erythema nodosum, pyoderma gangrenosum, oral lesions (discussed in detail in later sections), uveitis, hepatic steatosis, primary sclerosing cholangitis, and metabolic bone disease<sup>50-67</sup>. Both UC and CD patients are at a higher risk of developing colorectal cancer, although the risk is greater in UC than CD<sup>68,69</sup>. IBD patients experience a diminished quality of life and have a lower life expectancy compared to the general population<sup>70,71</sup>.

Between 1990 and 2017, the global incidence of IBD surged by 31%, affecting around 6.8 million people worldwide and becoming a major public health concern<sup>72-75</sup>. The incidence of IBD varies, with highest rates observed in North America, Western Europe, and Australia<sup>74,75</sup>. The prevalence of IBD in the United States is estimated to be over 1.6 million, with 780,000 diagnosed with CD and 907,000 with UC<sup>73,76,77</sup>.

The etiology of IBD remains largely unclear, but it is believed to result from a complex interplay between genetic, environmental, microbial factors, and the host immune responses<sup>78-83</sup>. Over 200 genetic loci related to immune regulation, intestinal barrier function, and other biological pathways have been associated with IBD, suggesting a strong genetic influence<sup>78,84-89</sup>. Notable genetic loci include *NOD2* (one of the first genetic loci identified as a risk factor for CD), *IL23R*, *ATG16L1*, *IRGM*, *PTGER4*, *TNFSF15*, and *IRF8*<sup>78,84-89</sup>. Previously, our group and others have identified several single nucleotide polymorphisms (SNPs) located 1.7-60kb downstream of *IRF8* as risk factors for UC and CD<sup>87,88,90-100</sup> (**Figure 1**). *IRF8* SNPs are significantly associated with CD in Ashkenazi Jews, who have a four- to seven-fold-higher incidence of CD than non-Ashkenazi European Jews<sup>96,101</sup>. *IRF8* is expressed in the intestinal epithelial cells (IECs) in a gradient pattern, with highest expression in the differentiated cell zones and low levels in the proliferating and stem cell zones<sup>102,103</sup>. *IRF8* functions as a suppressor of colonic inflammation. *IRF8* deficiency in IECs is linked to colitis-related colon tumorigenesis in both humans and mice<sup>102,104,105</sup>. In mice, *IRF8* deficiency promotes colitis mediated by Th17 and Tfh cells<sup>104,105</sup> and impairs gastric innate immunity against infection<sup>106</sup>. Dysregulation of IRF/IFN-I signaling is extensively involved in IBD pathogenesis and targeting this pathway represents a promising intervention strategy for IBD<sup>107</sup>. Additionally, we have shown that *IRF8* is also critical for periodontal homeostasis<sup>108-110</sup>.

Collectively, these findings highlight the importance of IRF8 in intestinal health and establish the critical value of *Irf8*-deficient mice in providing novel insights into human GI diseases.

Some of the identified risk factors for IBD include: (a) Family history: individuals with a first-degree relative with IBD face a higher risk of developing the condition<sup>111,112</sup>; (b) Age: IBD is more commonly diagnosed in individuals under the age of 30 years, although it can occur at any age. Historically believed to be a disease of children and young adults (20-30 years), it is now recognized that 10-15% of patients develop IBD after the age of 60 years (older adults)<sup>113-117</sup>. The cause of older-onset IBD is unclear, but it is thought to be less associated with genetics and more influenced by age-related changes in the immune system and gut microbiome<sup>113,118-121</sup>; (c) Ethnicity: IBD is more common in Caucasians and people of Ashkenazi Jewish descent<sup>96,101,111,122,123</sup>; and (d) Smoking: cigarette smoking increases the risk of CD and may exacerbate its progression, while it appears to have a protective effect against UC<sup>124,125</sup>.

The course of IBD varies, with some experiencing periods of remission while others endure frequent relapses. IBD may lead to complications such as strictures, fistulas, or colorectal cancer<sup>40-47</sup>. Disease severity and treatment response significantly influence prognosis. Currently, there is no cure for IBD, and the primary management focuses on resolving inflammation, preventing flare-ups and other complications, and improving quality of life<sup>126-128</sup>. Treatment options include - (a) Medications: anti-inflammatory drugs, immunosuppressants, biologic therapies, and small molecules<sup>129-131</sup>; (b) Nutrition: dietary modification and nutritional supplementation may help manage symptoms and promote healing<sup>132-134</sup>; and (c) Surgery: in cases of severe inflammation,



strictures, or fistulas, surgery may be necessary to remove the affected portion of the intestine<sup>135-137</sup>.

### **Oral Manifestations of IBD**

Extraintestinal manifestations of IBD, which can affect nearly all organ systems, are common in both UC and CD<sup>50-55</sup>. Approximately 10-30% of IBD patients exhibit oral manifestations of the disease, which can precede, coincide with, or follow the onset of GI symptoms<sup>56-58,63,64,67</sup>. Commonly observed oral manifestations include aphthous ulcers, cobblestoned oral mucosa, pyostomatitis vegetans, gingivitis, periodontitis, angular cheilitis, and oral lichen planus<sup>37,56-67,138,139</sup>. Additionally, some individuals may present with halitosis, atrophic glossitis, burning mouth syndrome, and xerostomia<sup>56-67</sup>. Some of these lesions are more common in CD versus UC, and more frequently noted in children versus adults<sup>140</sup>.

The etiology of oral manifestations in IBD is complex and not fully understood; however, it is believed to involve a combination of genetic predisposition, immune dysregulation, and alterations in the oral microbiome<sup>56-67</sup>. Several studies underscore the role of cytokine activity in both the GI and oral regions. Elevated levels of IL-6, IL-8, IL-1 $\beta$ , TNF- $\alpha$ , and MCP-1 have been noted in saliva and gingival tissues of patients with active IBD versus nonactive IBD or healthy controls<sup>141-144</sup>. Higher levels of chemokines CXCL-8, -9, and -10 have been identified in the buccal mucosal of children with CD compared to healthy children and adult CD patients<sup>145</sup>. Mutations in IL-10RA and IL-10RB, which disrupt the IL-10/STAT3 cascade, have been associated with pediatric IBD<sup>146,147</sup>. Patients deficient in IL-10 and IL-10R may exhibit recurrent aphthous ulcers due to subtle immunological abnormalities, including decreased CD4<sup>+</sup>/CD8<sup>+</sup> T-cell ratios and

dysregulated serum immunoglobulin levels<sup>148,149</sup>. Schmidt et al. identified higher concentrations of activated matrix metalloproteinase-8 (MMP-8) in the gingival crevicular fluid (GCF) of IBD patients compared to healthy controls<sup>150</sup>. Figueredo et al. reported decreased IL-4 levels and elevated serum IL-18 levels in UC patients, with the latter positively correlated with IL-1 $\beta$  in the GCF, which likely contributed to periodontitis development<sup>151</sup>. Likewise, Enver et al. reported a significant elevation in IL-1 $\beta$  concentrations within GCF, alongside increased TNF- $\alpha$  and reduced IL-10 levels in the saliva of UC patients diagnosed with periodontitis<sup>152</sup>. Low levels of IL-10 are unable to inhibit the production of pro-inflammatory cytokines, such as IL-6, TNF- $\alpha$ , IFN- $\gamma$ , and IL-17, resulting in higher IL-17/IL-10 ratio that may serve as a key indicator of disease severity and progression due to its association with intestinal and extra-intestinal features<sup>153,154</sup>.

Conversely, IBD may immunologically trigger oral manifestations, partially due to the recognition of common epitopes throughout the body. The extraintestinal manifestations of IBD could stem from a broad adaptive immune response triggered by local intestinal dysbiosis, leading to recognition of these epithelial epitopes in other organs and the oral cavity, ultimately causing extraintestinal pathologies<sup>54,155-157</sup>. A molecular similarity between gut microbiota antigens and nonmicrobial epitopes present on cells in the oral cavity could potentially lead to immune cross-reactivity<sup>158,159</sup>. Furthermore, in IBD, local immune responses to gut dysbiosis may initiate systemic T cell-mediated responses and cytokine production<sup>160,161</sup>, which could lead to induction of oral lesions. In response to antigenic stimulation, T cells migrate to the oral mucosa, where CD8<sup>+</sup> T lymphocytes, accompanied by infiltrating macrophages and neutrophils, may cause epithelial damage and ulceration commonly observed in pyostomatitis vegetans<sup>162</sup>. Overexpression of pro-inflammatory cytokines such as IL-6, IL-8, and TNF- $\alpha$  in pyostomatitis

vegetans can lead to the recruitment of inflammatory cells to UC lesions, thus synergistically contributing to the pro-inflammatory pathogenesis of pyostomatitis vegetans and IBD<sup>162</sup>. Collectively, these studies suggest that immune system dysregulation may be an important link bridging the oral cavity and the intestines.

Several studies have suggested that oral microbial dysbiosis, and secondary inflammatory responses within the gut, might potentially contribute to oral manifestations in IBD<sup>54,63,163,164</sup>. Remarkably, the periodontal inflammation in IBD does not appear to correlate with plaque accumulation, giving rise to the notion that systemic inflammation associated with IBD could induce alterations in the oral microbiome, consequently intensifying oral inflammation<sup>165,166</sup>. An overabundance of specific oral bacteria, including *Streptococcus*, *Prevotella*, *Veillonella*, and *Haemophilus* in the oral cavity is linked to inflammatory responses triggered by reduced salivary lysozyme and increased IL-1 $\beta$  levels, which may be associated with gut microbial dysbiosis<sup>141</sup>. These changes are connected to heightened oxidative stress and virulence (e.g., metabolism of terpenoids, polyketides, carbohydrates and lipids, and biosynthesis of secondary metabolites), enzyme activity (e.g., protein kinases), bacterial aggression (e.g., bacterial toxins and invasion of epithelial cells), and apoptosis in the oral region, implying a connection between oral microbial dysbiosis and IBD<sup>167</sup>. Altered salivary lysozyme levels could be related to gut imbalance and subsequent periodontitis development<sup>168</sup>. Furthermore, intestinal dysbiosis has been linked to chronic inflammatory state and activation of gut-associated lymphoid tissue (GALT)<sup>169,170</sup>, which could potentially lead to extraintestinal pathologies<sup>171</sup>. The proven effectiveness of adjuvant probiotic therapy in treating oral ulcers supports the hypothesis that oral ulcers in IBD might result from a combination of intestinal dysbiosis and other factors, such as oral mucosa microtraumas<sup>172</sup>.

Collectively, these findings indicate a possible correlation between oral and gut microbial dysbiosis and the occurrence of oral manifestations in IBD.

### **Historical Perspective of Oral-Gut Interconnection**

Over the years, numerous case reports have contributed to our understanding of oral and gut interconnection. The first report of oral involvement in IBD, by Dudeney and Todd in 1969, described a CD patient who developed granulomatous lesions in the left buccal mucosa 16 years after the initial diagnosis<sup>173</sup>. In 1972, Bottomely et al. documented a case of teenage girl with CD who exhibited gingival hyperplasia across maxillary anterior teeth, with 5-6 mm "pseudopockets" indicative of a severe hyperplastic phenotype that worsened periodically<sup>174</sup>. In 1972, Croft et al. retrospectively analyzed 332 CD patients and found that 6.1% had developed oral ulcers at some point during their illness<sup>175</sup>. In 1975, a systematic study by Asquith et al. involving 100 CD patients, 100 UC patients, and 100 healthy controls matched for age, sex, and denture status reported that 9% of CD and 2% of UC patients developed oral lesions with macroscopic and histological features similar to those in the GI tract<sup>163</sup>. Additionally, they noted salivary IgA production was reduced in CD patients with active bowel disease<sup>163</sup>. In 1982, Lamster et al. analyzed polymorphonuclear leukocytes from 30 patients with active or inactive IBD and reported that those with active IBD had higher levels of circulating immune complex activity and their peripheral neutrophils exhibited greater metabolic activity compared to inactive IBD or healthy controls<sup>176</sup>. Additionally, a higher prevalence of oral pathologies was observed among subjects with active IBD. In 1986, Van Dyke et al. evaluated 20 IBD patients with and without periodontal disease and found that the periodontal flora of IBD patients predominantly consisted of small, motile, gram-negative rods, closely related to the genus *Wolinella*<sup>177</sup>. All 10 IBD subjects with

periodontal disease exhibited serum-mediated defect in neutrophil chemotaxis, while neutrophil phagocytosis was normal. Additionally, PGE2 levels in GCF from IBD patients with periodontal disease were four-fold higher than in adult periodontitis patients without IBD<sup>177</sup>.

Building upon these initial case reports, cross-sectional studies were designed to explore the positive correlation between IBD and periodontitis-afflicted individuals. In 1991, Flemmig et al. examined the periodontal status of 107 IBD patients and identified a 12% higher prevalence of periodontal disease but a 0.6 mm lower clinical attachment loss in IBD patients when compared to the general US adult population<sup>178</sup>. In 2006, Grössner-Schreiber et al. examined 62 IBD patients and 59 healthy controls and found that IBD patients exhibited a significantly higher incidence of caries, but no distinct differences in periodontal findings<sup>179</sup>. In contrast, Brito et al. in 2008 examined 99 CD, 80 UC, and 74 healthy controls and found a significantly higher prevalence of periodontitis in UC (90%) and CD (82%) patients when compared to healthy controls (68%)<sup>138</sup>. Altogether, these studies provide some of the earliest evidence for the oral-gut axis, highlighting the potential connection between periodontitis and IBD. Over the next several years, similar studies have been published expanding our knowledge about periodontitis-IBD interconnection. **Table 1** summarizes recent studies demonstrating associations between periodontitis and IBD.

Currently, limited evidence suggests that IBD treatment can improve periodontal disease outcomes, and vice versa, hinting that both diseases might share common altered immune-inflammatory mechanisms. IBD patients treated with anti-TNF- $\alpha$  biologics experienced rapid healing of apical periodontitis compared to controls<sup>180</sup>. Corticosteroids, which are often used in IBD management, seem to confer a protective effect against periodontitis<sup>181</sup>. In UC patients

responsive to biologics treatment, salivary levels of IgA and MPO significantly increased, suggesting that successful UC therapy may also boost oral defense mechanisms<sup>182</sup>. Furthermore, biologics used to treat other chronic inflammatory diseases appear to hinder periodontitis progression and enhance the healing response to periodontal treatment<sup>183</sup>. Conversely, periodontitis treatment with mesenchymal stem cell-derived exosomes attenuated experimental colitis in murine models<sup>184</sup>. Taken together, these findings indicate that the immune-modulating effect of certain drugs might not only improve IBD outcomes, but also reduce inflammation within periodontal tissues. Moreover, periodontitis treatment could have positive effects on IBD outcomes. Nonetheless, it's crucial to note that immunomodulators commonly used in IBD management, such as corticosteroids, aminosalicylates, methotrexate, anti-TNF- $\alpha$ , and other biologics, could increase the risk of opportunistic infections in the oral cavity<sup>65</sup>.

### **A Multi-hit Model of Periodontitis-Mediated IBD Pathogenesis**

Every day, the average adult generates and ingests ~1.5 L of saliva, which contains  $\sim 1.5 \times 10^{12}$  oral bacteria<sup>185-189</sup>. In healthy individuals, several defense mechanisms prevent ingested oral bacteria from colonizing the gut and promoting IBD. These include: (a) physical barrier provided by the mucus layer along with IECs<sup>190</sup>, (b) bacterial clearance by mucus<sup>191</sup>, (c) competition between indigenous gut microbes and exogenous microbes invading from the mouth<sup>192,193</sup>, and (d) gastric acid and pepsin destroy opportunistic pathogens that enter the stomach<sup>194,195</sup>. However, when these defense mechanisms are breached by genetic abnormalities, systemic disorders, gut dysbiosis, medications, and other factors, oral microbes can disseminate to the intestine, potentially disrupting intestinal homeostasis and abnormally activating the intestinal immune system, thereby influencing IBD development<sup>3,193,196-203</sup>.

The mucus layer rich in antimicrobial peptides and secretory immunoglobulins prevents direct contact between pathogens and the epithelium and creates a hostile environment for potential invaders<sup>204,205</sup>. Conditions such as cystic fibrosis, stress, infection, an unhealthy diet, and aging can disrupt the mucus layer, facilitating bacterial penetration<sup>120,206-208</sup>. Beneath the mucus, the IEC barrier, fortified by occludins, claudins, and other junction proteins, provides another layer of protection<sup>209</sup>. Disruption of the IEC barrier can result in a "leaky" gut, permitting microorganisms and intestinal contents to infiltrate the mucosal barrier and initiate inflammation<sup>210</sup>. Further, the resident commensal microbiota resist exogenous pathogen colonization through nutrient competition and niche occupation<sup>192,211,212</sup>. These microbes ferment dietary fibers, producing short-chain fatty acids (SCFAs) that serve as an energy source for colonocytes and exhibit anti-inflammatory properties<sup>213</sup>. However, a shift in microbial equilibrium, or dysbiosis, frequently induced by triggers such as antibiotic overuse or dietary changes, can exacerbate IBD risk<sup>214</sup>. Chemical barriers, including gastric acid and pepsin in the stomach, help thwart opportunistic pathogens<sup>194,195</sup>. However, hypochlorhydria or prolonged use of proton pump inhibitors may predispose individuals to bacterial overgrowth and infections like *Clostridium difficile*<sup>215</sup>. Collectively, the compromised mucus layer and epithelial barriers, coupled with a dysbiotic state of gut microbiota and heightened immune responses, can increase the risk for IBD. Based on these findings, we propose a multi-hit model to illustrate how periodontitis and related oral bacteria may enhance the susceptibility to IBD (**Figure 2**).

### **Stage 1: Initiation of Oral Dysbiosis**

In a host exhibiting homeostatic oral and gut compartments, oral bacteria neither proliferate nor translocate to the gut, thus maintaining a state of health. The onset of periodontitis causes oral dysbiosis, leading to the expansion of virulent oral bacteria<sup>216</sup>. There is an enrichment of gram-negative bacteria that can thrive within anaerobic conditions, such as those found in the gut. Documentation of genetically identical strains of *F. nucleatum* and *C. concisus* in both the oral cavity and the intestines of IBD and colorectal cancer patients indicates microbial adaptations that promote oral-to-gut transmission<sup>217,218</sup>.

## **Stage 2: Oral Bacteria Translocation and Intestinal Colonization**

The next stage involves oral bacteria translocation to the intestine, either via ingestion or through the circulatory system (bacteremia). Normally, more than 99% of swallowed oral microorganisms are inactivated as they pass through the stomach<sup>189,219</sup>. However, several conditions such as gastric ulcers, gastroesophageal reflux disease, genetic disorders, an unhealthy diet, aging, stress, and the use of tobacco, alcohol, antibiotics, non-steroidal anti-inflammatory drugs, and/or proton-pump inhibitors may disrupt the intestinal barrier function and perturb the gut microbiota ecosystem, thus disrupting colonization resistance and facilitating the establishment of oral bacteria in the gut<sup>120,206-208,214,215,220-222</sup>. A 10-fold increase in ileal *Fusobacteriaceae* was noted following antibiotic usage<sup>223</sup>. Similarly, increased intestinal colonization of oral bacteria was noted in individuals using proton pump inhibitors<sup>224,225</sup>. Additionally, periodontitis can lead to bacteremia, with *P. gingivalis*, *F. nucleatum*, *T. denticola*, and *P. intermedia* capable of evading immune surveillance and proliferating within the immune cells<sup>9,226</sup>, and potentially exacerbating IBD development.



### **Stage 3: Induction of Intestinal Inflammation**

In homeostasis, gut-resident microbes promote development of bacterium-specific tolerogenic responses against commensals, that do not elicit intestinal inflammation<sup>227,228</sup>. However, when certain exogenous oral pathogens colonize the gut, they can opportunistically elicit pathogenic immune responses. After epithelial disruption, ingested oral bacteria can interact with gut-associated immune cells stimulating production of pro-inflammatory cytokines such as IL-17, IL-1 $\beta$ , and IFN- $\gamma$ <sup>200,229</sup>. Furthermore, oral pathogen-reactive Th17 cells that arise *de novo* in the oral cavity can migrate to the inflamed gut, where they are activated by ectopically colonized oral pathogens, and subsequently contribute to gut inflammation<sup>200</sup>. Thus, periodontitis can exacerbate gut inflammation by supplying the gut with both colitogenic oral pathogens and pathogenic T cells<sup>200</sup>.

In summary, having oral dysbiosis or gut barrier disruption alone is insufficient to render the host susceptible to IBD. However, the simultaneous presence of oral dysbiosis (providing an adequate supply of oral pathogens) and impaired gut resistance (disrupted barrier function against oral pathogens) creates necessary conditions for successful gut colonization by oral pathogens, which then promotes intestinal inflammation by activating innate and adaptive immune responses.

### **Oral and Gut Microbiome**

The oral microbiota ranks as the second-largest microbial community after the gut microbiota. It harbors more than 700 species and 1,300 bacterial strains, along with a diverse array of ultrasmall Candidate Phyla Radiation bacteria, fungi, amoebae, flagellates, archaea, and viruses<sup>24,27,186,230-237</sup>. In health, the oral microbiota is remarkably stable and dominated by

commensal bacteria such as *Streptococcus*, *Actinomyces*, *Haemophilus*, and *Neisseria*, which maintain a dynamic equilibrium with the host, ensuring symbiosis and facilitating normal immune and metabolic functions within the oral cavity<sup>9,18,20,232,238</sup>. However, when this balance is disrupted, it can lead to dysbiosis, resulting in periodontitis<sup>9,18,20,25,232,238</sup>. Oral dysbiosis is characterized by the overgrowth of anaerobic bacteria such as *P. gingivalis*, *T. forsythia*, *T. denticola* (collectively referred to as the "red complex"), and other species within the phyla *Firmicutes*, *Proteobacteria*, *Spirochaetes*, and *Bacteroidetes*<sup>9,18,20,25,232,238</sup>. These dysbiotic bacteria produce virulence factors that promote tissue destruction, impair host immune defenses, and disrupt the oral microbial community's stability<sup>18</sup>. While the dysbiotic microbiota enriched in virulence factors triggers periodontitis, it is the host's hyperactive immunoinflammatory responses to the altered microflora that cause major destruction of tooth-supporting structures<sup>19,21</sup>.

*P. gingivalis* is a keystone periodontal pathogen, which adheres to mucus membranes, periodontal pocket epithelium, and other bacterial surfaces through adhesion factors such as fimbriae, hemagglutinins, proteases, and adhesins<sup>239-241</sup>. *P. gingivalis* produces a range of virulence factors, including endotoxins (e.g., lipopolysaccharide (LPS)), proteases (e.g., gingipains), outer membrane vesicles, acid and alkaline phosphatases, and organic acids, that contribute to the degradation of host proteins and evasion of host immune defenses<sup>240-243</sup>. Consequently, this leads to clinical manifestations such as edema, neutrophil infiltration, and hemorrhage. In addition to *P. gingivalis*, other periodontal pathogens, such as *A. actinomycetemcomitans*, *F. nucleatum*, *T. forsythia*, and *P. intermedia*, play crucial roles in the pathogenesis of periodontitis<sup>23,244-248</sup>. *A. actinomycetemcomitans* is a facultative anaerobe and its key virulence factors include leukotoxin (LtxA), which selectively targets immune cells, cytolethal

distending toxin (Cdt) that induces cell cycle arrest and apoptosis in multiple cell types, and adhesins that promote bacterial attachment to host tissues and other oral microbiota<sup>246-250</sup>. Additionally, its LPS triggers inflammation, and the extracellular matrix-degrading enzymes lead to tissue destruction, together orchestrating the complex pathophysiological processes underlying periodontitis. *F. nucleatum* is an anaerobic bacterium known to promote biofilm formation and support the growth of other periodontal pathogens<sup>244,245,251</sup>. It produces various virulence factors, including adhesins, hemagglutinins, and proteases, that contribute to tissue destruction and evasion of host defenses<sup>252,253</sup>. *T. forsythia*, another important periodontal pathogen, produces virulence factors such as proteases (e.g., karilysin and mirolase) and surface structures like the BspA protein, which facilitate tissue invasion and immune evasion<sup>254,255</sup>. The combined actions of multiple periodontal pathogens and their virulence factors contribute to the molecular mechanisms underlying periodontitis<sup>240-255</sup>.

As two extremities of the digestive tract, the oral cavity and the intestine exhibit shared microbial pathogenesis mechanisms. Imbalances in the gut microbial community can precipitate alterations in bacterial metabolites and the release of numerous virulence factors, leading to host tissue damage and inflammatory responses<sup>192,256-258</sup>. In a healthy state, the gut microbiota is primarily composed of *Firmicutes*, *Bacteroidetes*, *Proteobacteria*, and *Actinobacteria*, with smaller populations of *Fusobacteria* and *Cyanobacteria* contributing to the overall diversity<sup>256,259-261</sup>. Additionally, archaea, fungi, and viruses colonize the human GI tract. This intricate microbial community maintains gut homeostasis by executing essential functions such as nutrient metabolism, immune modulation, and defense against pathogens<sup>256,259-263</sup>. The host tissues offer a nutrient-rich environment, reciprocated by the gut microbiota through the production of SCFAs

and essential vitamins, fostering a mutually beneficial symbiosis<sup>261,263</sup>. However, in IBD, the gut microbiota undergoes ecological dysbiosis, characterized by reduced microbial diversity, a decrease in beneficial commensal bacteria (e.g., Firmicutes), and an increase in potentially pathogenic bacteria (e.g., Proteobacteria)<sup>256,259-261</sup>. This dysbiosis leads to reduced production of beneficial metabolites such as SCFAs and an increase in pro-inflammatory molecules, which can further exacerbate the intestinal inflammation and compromise the intestinal barrier function<sup>256,259-261</sup>. As a result, the delicate balance between the host and the gut microbiota is disrupted, leading to a vicious cycle of inflammation and tissue damage that characterizes IBD.

Clinical and animal studies have demonstrated an emerging microbial signature in IBD, characterized by the expansion of oral-associated bacteria. **Table 2** summarizes various clinical studies demonstrating evidence of oral bacterial species enriched in the intestinal tissues of patients with IBD and colorectal cancer (another disease implicated in the oral-gut axis). In an early study, Van Dyke et al (1986) investigated differences in the oral microbiome among IBD, periodontitis patients, and healthy controls<sup>177</sup>. In IBD patients, they observed a predominant presence of gram-negative rod-shaped bacteria, closely related to the genus *Wolinella*. Interestingly, periodontitis-free IBD patients displayed a decreased bacterial load within the gingival sulcus compared to their counterparts with periodontitis. These findings suggest distinct variations in the oral microbiome of IBD patients compared to periodontitis patients and healthy controls. Meurman et al. (1994) found higher salivary yeast, *Lactobacilli*, and *S. mutans* counts in individuals with active CD compared to inactive CD<sup>264</sup>. Stein et al. (2010) detected higher frequencies of *C. rectus* (94.6%), *A. actinomycetemcomitans* (76.9%), *P. gingivalis* (62.6%), *P. intermedia* (79.6%), and *T. forsythia* (64.6%) in subgingival plaque from 147 CD patients stratified for *CARD15*-gene mutations<sup>265</sup>.

Notably, this study did not include a control group for comparative analysis. Man et al. (2010) and Strauss et al. (2011) identified a higher abundance of *C. concisus* and *F. nucleatum* in feces and intestinal biopsies of IBD patients, suggesting that viable *C. concisus* and *F. nucleatum* can migrate to the intestines and establish themselves in the mucosal environment<sup>266,267</sup>. Docktor et al. (2012) investigated the oral microbiome of children and young adults with IBD by analyzing tongue and buccal mucosal brushings<sup>268</sup>. They found a significant decrease in *Fusobacteria* and *Firmicutes* in CD patients compared to healthy controls. In UC patients, a similar decrease in *Fusobacteria* was observed, while *Spirochaetes*, *Synergistetes*, and *Bacteroidetes* were increased compared to controls. Brito et al. (2013) investigated 45 untreated periodontitis patients with either CD or UC, and patients with untreated periodontitis as controls<sup>38</sup>. They found CD patients harbored significantly higher concentrations of *B. ureolyticus*, *C. gracilis*, *P. melaninogenica*, *S. aureus*, *S. anginosus*, *S. intermedius*, and *S. mutans* compared to UC and controls subjects. Said et al. (2014) analyzed saliva from 21 CD, 14 UC patients, and 24 healthy controls, and found higher abundance of *Bacteroidetes*, *Prevotella*, and *Veillonella* in CD and UC patients compared to healthy controls, while *Proteobacteria*, *Streptococcus*, and *Haemophilus* were lower<sup>141</sup>. *Neisseria* and *Gemella* were also lower in CD patients versus healthy controls. Kelsen et al. (2015) characterized subgingival microbiota in pediatric patients with active or non-active CD and identified 17 genera more abundant in CD patients versus healthy controls, including *Capnocytophaga*, *Rothia*, and *TM7*<sup>269</sup>. Both antibiotic exposure and disease state were linked to differences in bacterial community composition. Schmidt et al. (2018) examined subgingival plaque and found a significantly lower prevalence of *E. nodatum* and *E. corrodens* in 59 IBD patients compared to 59 healthy controls<sup>150</sup>. Xun et al. (2018) investigated oral microbial dysbiosis in saliva samples from 54 UC patients, 13 active or remissive CD patients, and 25 healthy adults. They found an

enrichment of *Streptococcaceae* and *Enterobacteriaceae* in UC, *Veillonellaceae* in CD, and depletion of *Lachnospiraceae* and *Porphyromonadaceae* in UC, as well as *Neisseriaceae* and *Haemophilus* in CD patients<sup>167</sup>. Alpha diversity was significantly lower in UC and CD patients. Recently, Kitamoto et al. (2020) showed that *Klebsiella* spp. from the oral cavity can translocate to the gut, where they activate the inflammasome in lamina propria macrophages, exacerbating gut inflammation<sup>200</sup>.

### **Shared Immunoinflammatory Responses**

The pathogenesis of both periodontitis and IBD involves a complex interplay between host immunity and specific bacterial stimuli<sup>270</sup>. Here, we discuss the sequence of events involving immune cell activation by specific oral bacteria contributing to periodontitis-mediated IBD progression, elaborating on the mechanistic details of the roles of neutrophils, macrophages, dendritic cells (DCs), T cells, and B cells in the process. Oral pathogen-mediated immune responses that drive gut inflammation in IBD are concisely illustrated in **Figure 3**.

**Neutrophils**, as the first responders to bacterial invasion, play a pivotal role in the initial stages of periodontitis and IBD<sup>9,271-275</sup>. In periodontitis, *P. gingivalis*, through its virulence factors such as gingipains, promotes a hyperactive and sustained neutrophilic response, leading to elevated release of proteolytic enzymes and reactive oxygen species<sup>9,271,276</sup>. This results in collateral tissue damage and subsequent alveolar bone loss, a hallmark of periodontitis. Moreover, *P. gingivalis* can dysregulate neutrophil function, such as impairing neutrophil extracellular trap (NET) formation and phagocytosis, leading to an imbalanced host response<sup>9,271,276</sup>. In IBD, similar

neutrophil dysfunctions are observed, where excessive and sustained neutrophilic infiltration in the intestinal mucosa contributes to chronic inflammation and tissue damage<sup>273,274,277</sup>. Furthermore, neutrophil dysregulation, including abnormal recruitment and impaired clearance, is also seen in IBD<sup>273,274,277</sup>. *P. gingivalis* may dysregulate neutrophil function, potentially exacerbating IBD pathogenesis. Systemically circulating neutrophils in individuals with periodontitis exhibit cytokine hyper-reactivity and impaired chemotaxis, which could potentially contribute to the oral–gut axis in the context of IBD<sup>176,177,278</sup>. S100A8, S100A9, and S100A12 are small calcium-binding proteins abundantly expressed by neutrophils in acute inflammation and have been implicated in immune regulation in both periodontitis and IBD<sup>279-281</sup>. Higher salivary expression of S100A12 has been found in UC patients with periodontitis<sup>282</sup>. The role of S100 proteins in periodontitis-IBD pathogenesis needs to be further investigated.

**Macrophages**, key players in immune response, are implicated in both periodontitis and IBD. In the context of periodontitis, *P. gingivalis* can influence macrophage polarization, favoring a pro-inflammatory (M1) phenotype over an anti-inflammatory (M2) phenotype, thus promoting inflammation and tissue damage<sup>283</sup>. *F. nucleatum* also stimulates M1 macrophage polarization via the AKT2 pathway and fosters Th1 and Th17 cell expansion through STAT3 signaling<sup>284,285</sup>. Similar macrophage polarization patterns are seen in IBD, contributing to a sustained inflammatory environment in the gut<sup>286,287</sup>. Specifically, *Enterobacteriaceae* such as *Klebsiella* isolated from the oral cavity trigger IL-1 $\beta$  secretion from macrophages, intensifying intestinal inflammation by mediating IL-1 signaling<sup>200</sup>. Intriguingly, *Enterobacteriaceae* isolated from the intestines do not evoke similar IL-1 $\beta$  secretion, suggesting a specific response to oral microbes<sup>200</sup>.

**Dendritic cells (DCs)** are antigen-presenting cells that bridge innate and adaptive immunity<sup>288,289</sup>. DCs play a crucial role in maintaining oral tolerance to commensal bacteria and preventing unwanted inflammatory responses<sup>290</sup>. However, certain periodontal pathogens, like *P. gingivalis* and *A. actinomycetemcomitans*, can dysregulate DC function and promote inflammation<sup>291,292</sup>. In IBD, dysregulated DCs can initiate and perpetuate intestinal inflammation through an exaggerated T cell response<sup>293,294</sup>. Saliva from CD and UC patients can cause intestinal inflammation in mice lacking IL-10 through *Klebsiella*-induced DC signaling and Th1 activation<sup>229</sup>. In response to oral bacteria, IFN- $\gamma$ + CD4+ T cells accumulate in the intestinal mucosa of these mice, as observed in humans with CD.

**T cells** are key orchestrators of immune responses in both periodontitis and IBD, with their activation and subsequent modulation of inflammation serving as common pathogenic threads. *P. gingivalis* stimulates aberrant CD4+ T cell responses, tilting the balance towards a pro-inflammatory milieu. More specifically, *P. gingivalis* incites an increase in Th17 cell responses, characterized by distinct production of IL-17 and simultaneous modulation of the Th17/Treg ratio<sup>295,296</sup>. This results in an augmentation of Th17-related transcription factors and pro-inflammatory cytokines IL-17 and IL-6 via the TLR4 pathway, paralleled by downregulation of Foxp3, TGF- $\beta$ , and IL-10<sup>297</sup>. Further, *P. gingivalis* elicits intestinal inflammation by altering the gut microbiota composition and disrupting epithelial barrier function through IL-9-producing CD4+ T cells<sup>202</sup>. These shifts towards pro-inflammatory responses and a skewed T cell landscape could contribute to IBD progression<sup>296,297</sup>. *F. nucleatum* exacerbates this inflammatory cascade by compromising the integrity of the intestinal epithelial barrier, thereby increasing permeability and promoting secretion of inflammatory cytokines such as TNF- $\alpha$ , IFN- $\gamma$ , IL-1 $\beta$ , IL-6, IL-17, and in



parallel inhibiting the production of the anti-inflammatory cytokine IL-10<sup>285</sup>. In periodontitis, oral pathogen-reactive Th17 cells arise *de novo* in the oral cavity and migrate to the inflamed gut, where they are activated by ectopically colonized oral pathogens, and subsequently contribute to gut inflammation<sup>200</sup>. *Klebsiella* species, prevalent in the oral cavity of CD patients, have been shown to exploit this inflammatory landscape<sup>229</sup>. Upon intestinal colonization, *Klebsiella* induces Th1 cell responses via the innate immune receptor TLR4, leading to IL-10 deficiency and further amplifying inflammation<sup>229</sup>. Interestingly, *Klebsiella* also promote the expression of interferon-inducible (IFI) genes, which may facilitate colonization and subsequent recruitment of Th1 cells, thereby promoting a Th1-skewed inflammatory response reminiscent of IBD-like colitis<sup>229</sup>. Numerous studies have further delineated the shared inflammatory mechanisms between periodontitis and IBD by evaluating cytokine expression in affected tissues. For example, Menegat et al.<sup>298</sup> and Figueredo et al.<sup>144,151</sup> identified heightened levels of IL-17A, IL-17F, IL-22, IL-23, IL-25, IL-33, INF- $\gamma$  and IL-10 in gingival tissues of patients with IBD and chronic periodontitis. However, they found IL-1 $\beta$ , IL-4, IL-10, and IL-21 to be significantly elevated in patients with active IBD, suggesting an inflammation score based on IL-1 $\beta$ , IL-6, IL-21 and sCD40L expression, was higher in gingival tissues of active IBD patients. Furthermore, IBD patients treated with anti-TNF- $\alpha$  biologics had more rapid healing of apical periodontitis compared to controls<sup>180</sup>. Collectively, these studies underscore the intertwined relationship between periodontitis and IBD and the central role of T cell-mediated immune responses, thereby providing a clearer understanding of the common pathogenic landscape and potential targets for future therapeutics.

**B cells**, essential constituents of adaptive immunity that play a key role in the crosstalk between periodontitis and IBD, mediate their effects primarily through the production of

antibodies against specific pathogens. *P. gingivalis* can stimulate B cells to produce antibodies, such as IgG and IgA, but also fosters an environment of sustained inflammation in the oral cavity<sup>299,300</sup>. There is emerging evidence that B cell dysregulation and inappropriate antibody responses also contribute to IBD pathogenesis<sup>301</sup>. Our group recently demonstrated a highly dysregulated B cell response in UC, highlighting a potential role of B cells in disease pathogenesis<sup>302</sup>. We found expansion of naive B cells and IgG+ plasma cells with curtailed diversity and maturation within the mucosal B cell compartment of UC patients.

## **Current Knowledge Gaps and Future Directions**

### **Clinical and animal studies**

Although evidence supports the notion that periodontitis and IBD are interrelated, the specific mechanisms by which oral bacteria contribute to gut inflammation and vice versa are still unclear. The directionality and causality of this relationship are obscured by confounding factors. Tobacco use, a Western diet, and lifestyle are recognized risk factors for IBD, with some genes linked to mucosal barrier function and immune regulation potentially implicated<sup>40,82,83,303</sup>. However, the precise role of these factors remains unclear. Much of the existing research linking periodontitis and IBD is cross-sectional, limiting our understanding of causal relationships<sup>37,139,304-308</sup>. There is a need for longitudinal studies that can provide insights into the temporal sequence of these conditions, and whether periodontitis precedes, follows, or develops concurrently with IBD. To date, most studies have focused on bacterial dysbiosis, and the role of fungi and viruses has been neglected. It remains ambiguous whether dysbiosis acts as a primary cause of the disease or if it is simply a by-product of changes in the immune system, metabolism, or diet. Furthermore, the microbial dissimilarity between humans and mice raises questions about the applicability of

murine findings to humans. The role of various immune cells and the impact of trained immunity in both conditions remains ill-defined. The influence of age on the association between periodontitis and IBD is not fully clear. Age is a significant risk factor in the pathogenesis of both conditions, and understanding its role could potentially inform prevention and treatment strategies. Further it remains unanswered whether periodontitis treatment ameliorates IBD risk or severity, and if IBD management can reduce periodontitis occurrence. These significant knowledge gaps call for well-designed, robust, mechanistic clinical and animal studies to gain a comprehensive understanding of the interrelationships between periodontitis and IBD pathogenesis.

### **Concerns regarding the dextran sulfate sodium (DSS)-induced colitis model**

While several animal models (at least 66 different kinds) have been employed to study IBD pathogenesis<sup>309-312</sup>, we focus on the DSS-colitis model, which has been extensively used to investigate colitis pathogenesis and the potential causal link between periodontitis and IBD<sup>200,285,296,297,309-316</sup>. However, this model has inherent limitations that may impact the interpretation and translatability of oral and gut findings. DSS administration induces acute colonic inflammation by direct chemical injury to the intestinal epithelium<sup>309-312</sup>. The physical damage to the epithelial lining leads to luminal microbial ingress into the lamina propria, which stimulates innate and adaptive immune responses. This process differs from human IBD, which is a chronic condition characterized by alternating periods of inflammation and remission involving a complex interplay of genetic, environmental, and immunological factors<sup>40,82,83,303</sup>. While DSS is administered to cause colonic inflammation, it can have off-target effects on periodontal tissues and oral microbiota. Oz and Ebersole (2010) found that 2% DSS alone causes periodontal inflammation and significant alveolar bone loss in BALB/c mice<sup>317,318</sup>. Significant bone loss was

detected as early as 7 weeks after initiation of DSS treatment, progressing to severe periodontitis by 18 weeks. The authors concluded that DSS impacts mucosal tissue in a more generalized and systemic manner, affecting both the intestine and the oral cavity. Similarly, Mello-Neto et al. reported that DSS-treated rats exhibited inflammatory cells extending into periodontal connective tissues, which contained significantly elevated expression of Th1/Th2-related cytokines such as IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-6, IL-12, IL-13, GM-CSF, IFN- $\gamma$ , and TNF- $\alpha$ <sup>319</sup>. They concluded that DSS should be used with caution as it can lead to more widespread and indiscriminate lesions, and the increased pro-inflammatory cytokines in the gingival tissues caused by DSS alone might create an environment conducive to future alveolar bone loss. In another study, Rautava et al. showed that C57BL/6 male mice treated with 2% DSS for 1 week exhibited altered oral and gut microbiome composition, with a decrease in oral levels of *Spirochetes*, *Betaproteobacteria*, and *Lactobacillus*<sup>320</sup>. The salivary microbiota exhibited the most significant change when compared to the microbiota of the tongue and buccal mucosa. However, they noted no visible oral inflammation, and it is unclear how much of this is attributed to gender imbalance in the study. Additionally, Metzger et al.<sup>321</sup> and Hamdani et al.<sup>322</sup> demonstrated that DSS treatment suppresses bone formation and increases bone resorption, resulting in reduced bone mass and altered bone microarchitecture. In DSS-treated mice, elevated TNF- $\alpha$ , IL-6, RANKL, OPG, and sclerostin corresponded with higher osteoclast surfaces and lower rates of bone formation. Collectively, these findings suggest that DSS promotes periodontal inflammation, alveolar bone loss, and altered oral microbiota.

Based on these findings, the question arises whether DSS is a confounder in studying periodontal-IBD interconnection. While seminal studies in DSS-treated mice showed that bacteria

and immune cells from the oral cavity migrate to the gut and exacerbate colonic inflammation<sup>200</sup>, the extent to which this inter-relationship is confounded by DSS treatment is uncertain. Previous studies investigating the periodontitis-IBD interconnection lacked evidence that DSS treatment alone did not affect periodontal tissues, the oral microbiome, and oral immune cells<sup>200,285,296,297,313-316</sup>. This major limitation highlights the need for future research to focus on developing more accurate and representative animal models that better mimic the complex interactions between periodontitis, oral and gut bacteria, and IBD in humans. This may involve the use of alternative mouse models exhibiting increased susceptibility to both periodontitis and IBD without the need for chemical induction.

## **Conclusions**

As our understanding of periodontitis and IBD pathogenesis advances, both disorders represent a complex interplay of genetic, environmental, microbial, and immunological factors. Central to this conversation is the "multi-hit" model, suggesting that a sequence of events - dysbiosis of oral microbiota, a disrupted intestinal barrier function, and an aberrant immune response - are crucial for the development of periodontitis-associated IBD. The oral cavity may serve as a potential reservoir for intestinal pathogens. Oral bacteria and their byproducts can reach the gut through ingestion or systemic circulation. Factors such as genetic disorders, diet, aging, stress, and the use of tobacco, alcohol, or medications may disrupt the intestinal barrier function, allowing the oral bacteria to colonize the gut. Once colonized, these oral bacteria can elicit excessive immune response promoting intestinal inflammation. While current studies provide valuable insights, there is a need for longitudinal studies to provide an in-depth understanding of the periodontitis-IBD interconnection. Despite the valuable insights gained from DSS-colitis

animal models, their limitations must be carefully considered when exploring the interconnection between periodontitis and IBD. Lastly, collaboration between dentists, gastroenterologists, immunologists, and infectious disease experts/microbiologists, alongside other healthcare professionals, is necessary to provide holistic oral-systemic healthcare. Optimal dental care could reduce the supply of pathogenic oral bacteria to the gut, offering innovative methods to reduce the risk and severity of IBD.

### **Conflict of Interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### **Funding Sources:**

This work was supported by the National Institutes of Health grants R03DE029258 and R56DK131277 to V.T.M.; Univ. of Maryland School of Dentistry start-up funds and INSPIRE grants to V.T.M.; Merit Review Award BX004890 from the United States (U.S.) Department of Veterans Affairs Biomedical Laboratory Research and Development Program to J-P. Raufman (The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government); and The Bloomberg~Kimmel Institute for Immunotherapy, Johns Hopkins School of Medicine (CLS).

### **Author Contributions**

All authors have made substantial contributions to the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, and (3) final approval of the version to be submitted.

**Figure 1.** Schematic of *IRF8* gene structure with previously reported IBD single nucleotide polymorphisms (SNPs), genotypic changes, and P values.

**Figure 2. One hit, not enough wit – A multi-hit model: (red circle)** The onset of periodontitis leads to expansion of pathogenic oral bacteria. These bacteria can translocate to the intestine, either via ingestion or through the circulatory system. Normally, ingested oral bacteria are inactivated as they pass through the stomach. **(green circle)** Several factors, such as genetic disorders, medications, diet, smoking, alcohol, aging, and stress may disrupt intestinal barrier function and shift the gut microbiota long-term. This disruption can reduce colonization resistance, facilitating the establishment of oral bacteria in the gut. **(blue circle)** Once established in the gut, oral bacteria activate both innate and adaptive immune responses leading to intestinal inflammation. Oral dysbiosis or disrupted gut barrier alone are insufficient to predispose the host to IBD. Both a sufficient load of oral pathogens and disrupted barrier function are necessary for oral pathogens to successfully colonize the gut, which then activates immune responses leading to intestinal inflammation.

**Figure 3. Oral pathogen-mediated immune responses that drive gut inflammation in IBD.** Periodontitis onset triggers expansion of pathogenic oral bacteria. Constant saliva swallowing enables these bacteria to translocate to the gut. A compromised intestinal barrier function, marked by diminished mucus and epithelial barrier integrity, facilitates the penetration of oral bacteria into the sub-epithelial regions. Neutrophils, the first responders, attempt to phagocytose the ingested bacteria and release antimicrobial substances. Additionally, the antigen-presenting cells (APCs) in



the gut recognize the microbial invaders through pattern recognition receptors like Toll-like receptors (TLRs). Once activated, these cells release a cocktail of pro-inflammatory molecules: interleukin (IL)-6, IL-12, IL-23, IL-1 $\beta$ , tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), and chemokines. Consequently, these molecules guide the differentiation of naive T helper (Th0) cells into Th1, Th2, Th17, and Treg cells. Furthermore, B cells become activated by recognizing bacterial antigens and differentiate into plasma cells, which produce antibodies specific to the oral bacterial antigens. These antibodies neutralize or opsonize bacteria and can form immune complexes, intensifying inflammation. The concerted actions of innate and adaptive immune cells lead to initiation or exacerbation of the inflammatory process in IBD, highlighting the far-reaching effects of oral bacterial dysbiosis. Figure created with BioRender.com.

<b>Table 1: Studies Demonstrating Association Between Periodontitis and IBD</b>				
<b>Study (reference number)</b>	<b>IBD (n)</b>	<b>Non-IBD (n)</b>	<b>Periodontitis-IBD Associations</b>	<b>95% CI</b>
Grossner-Schreiber et al. 2006 <sup>179</sup>	IBD (62)	(59)	IBD (RR = 2.47) CAL $\geq$ 5mm	1.02–5.99
Habashneh et al. 2012 <sup>323</sup>	CD (59) UC (101)	(100)	CD (OR = 4.9) UC (OR = 7.0)	1.8–13.2 2.8–17.5
Vavricka et al. 2013 <sup>139</sup>	CD (69) UC (44)	(113)	CD (OR = 3.91) UC (OR = 3.94)	1.78–8.57 1.64–9.46
Chi et al. 2018 <sup>181</sup>	CD (6657)	(26,628)	(HR = 1.36)	1.25–1.48
Yu et al. 2018 <sup>324</sup>	CD (7) UC (20)	(108)	IBD (HR = 1.82) CD (HR = 3.95) UC (HR = 1.39)	1.09–3.03 1.59–9.82 0.69–2.46
Zhang et al. 2020 <sup>325</sup>	CD (265) UC (124)	(265)	CD (OR = 4.46) UC (OR = 4.66)	2.50–7.95 2.49–8.71
Bertl et al. 2022. <sup>306</sup>	IBD (1108)	(3429)	CD (OR = 1.74) UC (OR = 2.57)	1.36–2.24 1.99–3.32
Wang et al. 2023 <sup>305</sup>	IBD (12,882)	(21,770)	IBD (OR = 1.06)	1.01–1.12
Baima et al. 2023 <sup>37</sup>	CD (117) UC (60)	(180)	IBD (OR = 4.48) CD (OR = 4.01) UC (OR = 4.43)	2.30–8.73 1.92–8.38 1.66–11.81

IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; OR, odds ratio; HR, hazard ratio; RR, relative risk; CI, confidence interval; CAL, clinical attachment loss.

**Table 2. Oral Bacteria Enriched in the Intestines of Patients with IBD and Colorectal Cancer**

	<b>Study (reference number)</b>	<b>Study Design</b>	<b>Subjects (n)</b>	<b>Samples</b>	<b>Methods</b>	<b>Key Findings</b>
<b><i>Fusobacterium</i> spp.</b>  <b>(<i>F. nucleatum</i>)</b>	Strauss et al. 2011 <sup>267</sup>	Case-control	UC (4), CD (17), intermediate colitis (1), Healthy controls (32), IBS (2)	Colon biopsies	Isolation, culture, 16S rRNA sequencing	<i>Fusobacterium</i> spp. abundant in patients with GI disease (64%) versus healthy controls (26%). Highly invasive strains of <i>F. nucleatum</i> enriched in IBD patients.
	Castellarin et al. 2012 <sup>326</sup>	Cross-sectional	CRC (11)	CRC biopsies and adjacent normal tissues	Isolation, culture, RNA-seq, qPCR	Higher abundance of <i>Fusobacterium</i> in colorectal tumor specimens.
	Dejea et al. 2014 <sup>327</sup>	Cross-sectional	USA CRC/ Polyp (34), Healthy controls (62), MAL CRC/ Polyp (22)	Intestinal biopsies from CRC and healthy controls	16S rRNA sequencing	<i>Fusobacterium</i> predominant in non-biofilm CRC specimens and undetected in normal tissues.
	Gevers et al. 2014 <sup>223</sup>	Case-control	Pediatric CD (447), healthy controls (221)	Ileal and rectal biopsies, stool, serum	16S rRNA sequencing	<i>Fusobacteriaceae</i> enriched in treatment naïve CD patients and associated with disease progression. Oral species better represented in biopsies vs stool. Antibiotic use amplified the microbial dysbiosis associated with CD.
	Drewes et al. 2017 <sup>328</sup>	Case-control	MAL1 CRC (21), Polyp (1), Healthy controls (34); MAL2 CRC (23), Healthy controls (23); USA CRC (35), Polyp (4),	Stool, Intestinal biopsies from CRC, Polyp, and healthy tissues	16S rRNA sequencing	Oral pathogens, including <i>F. nucleatum</i> , <i>P. micra</i> , and <i>P. stomatis</i> highly enriched in CRC tissues.

			Healthy controls (60)			
Pascal et al. 2017 <sup>329</sup>	Case-control	UC (74), CD (87), healthy controls (111)	Stool	16S rRNA sequencing	<i>Fusobacterium</i> enriched in CD.	
Flemer et al. 2018 <sup>330</sup>	Case-control	CRC (99), colorectal polyps (32), Healthy controls (103)	Oral swab, colonic biopsies, stool	16S rRNA sequencing	<i>F. nucleatum</i> enriched in CRC, but also noted in healthy controls.	
Schirmer et al. 2018 <sup>331</sup>	Observational	Pediatric UC (405)	Rectal biopsies, stool	16S rRNA sequencing	<i>Fusobacterium</i> enriched and associated with disease progression, and twice higher in rectal biopsies vs stool.	
Dinakaran et al. 2018 <sup>332</sup>	Cross-sectional	Disease tissue from UC (13), CD (13), and adjacent healthy tissue (13)	Colonic biopsies	16S rRNA sequencing	<i>Fusobacterium</i> enriched in diseased colonic biopsies vs adjacent healthy tissue.	
Komiya et al. 2019 <sup>218</sup>	Cross-sectional	CRC (14)	Saliva, colonic biopsies	Isolation, culture, PCR, 16S rRNA sequencing	Identical <i>F. nucleatum</i> strains found in saliva and colon tumors.	
Vieira-Silva et al. 2019 <sup>333</sup>	Case-control	PSC (64), UC (13), CD (29), Healthy (1,120)	Stool	16S rRNA sequencing	<i>Fusobacterium</i> abundance associated with severity of intestinal inflammation.	
Liu et al. 2020 <sup>285</sup>	Case-control	UC (20), CD (71), healthy controls (43)	Stool	16S rRNA sequencing	<i>F. nucleatum</i> enriched and associated with disease activity in UC and CD patients. <i>F. nucleatum</i> infection in DSS-treated mice exacerbated colitis by promoting expression of IL-1 $\beta$ , TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and IL-17, and fostering CD4+T cell differentiation into	

						Th1 and Th17 cells.
<b><i>Porphyromonas</i> spp.</b>  <b>(<i>P. gingivalis</i>)</b>	Flemer et al. 2017 <sup>334</sup>	Case-control	CRC (59), colon polyps (21), healthy controls (56)	Stool, CRC biopsies and adjacent normal tissues	16S rRNA sequencing	Microbiota differed in CRC vs controls. Alterations were noted throughout the colon and not restricted to cancer.
	Ahn et al. 2013 <sup>335</sup>	Case-control	CRC (47), healthy controls (94)	Stool	16S rRNA sequencing	<i>Fusobacterium</i> and <i>Porphyromonas</i> were enriched in CRC, whereas <i>Clostridia</i> were decreased.
	Yang et al. 2019 <sup>336</sup>	Case-control	CRC (50), healthy controls (50)	Stool	16S rRNA sequencing, gas chromatography-mass spectrometry	CRC had less microbial diversity and enriched <i>Fusobacteria</i> , <i>Parvimonas</i> , and <i>Porphyromonas</i> ; 17 metabolites were specifically perturbed in CRC.
	Wang et al. 2021 <sup>337</sup>	Cross-sectional	Healthy (22), CRC (23), colorectal adenoma (32)	Stool, CRC, and normal tissue biopsies	16S rRNA sequencing, qPCR	<i>P. gingivalis</i> enriched in stool and biopsies of CRC and associated with poor prognosis. In <i>Apc<sup>Min/+</sup></i> mice, <i>P. gingivalis</i> promoted CRC by activating NLRP3 inflammasome.
	Lee et al. 2022 <sup>338</sup>	Case-control	CD (11), control (8)	Stool	16S rRNA sequencing	<i>Porphyromonadaceae</i> enriched in CD. <i>P. gingivalis</i> infection in DSS-treated mice exacerbated colitis by promoting expression of TNF- $\alpha$ and IL-6.
<b><i>Aggregatibacter</i> spp.</b>	Dinakaran et al. 2018 <sup>332</sup>	Cross-sectional	Disease tissue from UC (13), CD (13), and adjacent healthy tissue (13)	Colon biopsies	16S rRNA sequencing	<i>Aggregatibacter</i> , <i>Porphyromonas</i> , <i>Prevotella</i> , <i>Staphylococcus</i> , <i>Streptococcus</i> , enriched in diseased colon

						biopsies vs adjacent healthy tissue.
<b><i>Prevotella</i> spp.</b>	Atarashi et al. 2017 <sup>229</sup>	Case-control	UC (51), CD (7), PSC (27), GERD (18), alcoholic (16), healthy controls (150)	Saliva, Stool	Isolation, culture, 16S rRNA sequencing, metagenomic analysis	<i>Prevotella</i> , <i>Streptococcus</i> , <i>Neisseria</i> , <i>Rothia</i> , and <i>Gemella</i> enriched in UC, PSC, GERD and alcoholic feces.
	Dinakaran et al. 2018 <sup>332</sup>	Cross-sectional	Disease tissue from UC (13), CD (13), and adjacent healthy tissue (13)	Colon biopsies	16S rRNA sequencing	<i>Prevotella</i> enriched in diseased colon vs adjacent healthy tissue.
	Prasoodanan et al. 2021 <sup>339</sup>	Population-based	IBD (189) and healthy controls (200).	Stool	Whole metagenome sequencing	Higher abundance and diversity of <i>P. copri</i> in Indian and non-western versus western populations.
<b><i>Veillonellaceae</i> spp.</b> <b>(<i>V. parvula</i>)</b>	Gevers et al. 2014 <sup>223</sup>	Case-control	Pediatric CD (447), healthy controls (221)	Ileal and rectal biopsies, stool, serum	16S rRNA sequencing	<i>Veillonellaceae</i> enriched in CD and associated with disease progression. Oral species better represented in biopsies vs stool.
	Schirmer et al. 2018 <sup>331</sup>	Observational	Pediatric UC (405)	Rectal biopsies, stool	16S rRNA sequencing	<i>V. parvula</i> enriched and associated with disease progression, and higher in rectal biopsies vs stool.
	Vieira-Silva et al. 2019 <sup>333</sup>	Case-control	PSC (64), UC (13), CD (29), Healthy (1,120)	Stool	16S rRNA sequencing	<i>Veillonella</i> abundance associated with severity of intestinal inflammation.
<b><i>Klebsiella</i> spp.</b> <b>(<i>K. pneumoniae</i>)</b>	Atarashi et al. 2017 <sup>229</sup>	Case-control	UC (51), CD (7), PSC (27), GERD (18), alcoholic (16), healthy controls (150)	Saliva, Stool	Isolation, culture, 16S rRNA sequencing, metagenomic analysis	<i>Klebsiella</i> enriched in CD. Antibiotic-resistant <i>Klebsiella</i> tend to colonize when gut microbiota is dysbiotic and elicit severe inflammation in a genetically

						susceptible host by promoting Th1 cells.
	Lloyd-Price et al. 2019 <sup>340</sup>	Case-control	UC (38), CD (67), healthy controls (27)	Colon biopsies, stool, blood	16S rRNA sequencing, metagenomic, metatranscriptomic, proteomic, metabolomic analysis	<i>K. pneumoniae</i> and <i>H. parainfluenzae</i> levels during dysbiosis associated with acylcarnitines and bile acid levels.
	Imai et al. 2021 <sup>308</sup>	Case-control	UC (42), CD (18), healthy controls (45)	Saliva and stool	16S rRNA sequencing	<i>Enterobacteriaceae</i> enriched in CD patients with periodontitis.
<b><i>Streptococcus</i> spp.</b>	Pascal et al. 2017 <sup>329</sup>	Case-control	UC (74), CD (87), healthy controls (111)	Stool	16S rRNA sequencing	Higher abundance of <i>Streptococcus</i> noted in CD with post-operative recurrence compared to those who remained in remission.
	Atarashi et al. 2017 <sup>229</sup>	Case-control	UC (51), CD (7), PSC (27), GERD (18), alcoholic (16), healthy controls (150)	Saliva, Stool	Isolation, culture, 16S rRNA sequencing, metagenomic analysis	<i>Streptococcus</i> , enriched in feces of UC, PSC, GERD, and alcoholic patients.
	Vieira-Silva et al. 2019 <sup>333</sup>	Case-control	PSC (64), UC (13), CD (29), Healthy (1,120)	Stool	16S rRNA sequencing	<i>Streptococcus</i> abundance associated with severity of intestinal inflammation.
<b><i>Campylobacter</i> spp. (<i>C. concisus</i>)</b>	Man et al. 2010 <sup>266</sup>	Case-control	Pediatric CD (54), non-IBD (27), and healthy controls (33).	Stool	PCR	Higher prevalence of <i>C. concisus</i> noted in pediatric CD versus non-IBD and healthy controls.
	Kirk et al. 2016 <sup>341</sup>	Case-control	UC (16), CD (9), IPAA (27), and healthy controls (26)	Ileum and colon biopsies	Isolation, culture, and PCR	Higher abundance of <i>C. concisus</i> noted in IBD versus control.

IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; IBD, irritable bowel syndrome; CRC, colorectal cancer; PSC, primary sclerosing cholangitis; GERD, gastroesophageal reflux disease; GI, gastrointestinal; MAL1, Malaysian cohort 1; MAL2, Malaysian cohort 2; DSS, dextran sodium sulfate; IPAA, ileal pouch–anal anastomosis.

## Reference:

1. D'Souza RN, Collins FS, Murthy VH. Oral Health for All - Realizing the Promise of Science. *The New England journal of medicine*. 2022;386(9):809-811.
2. Somerman M, Mouradian WE. Integrating Oral and Systemic Health: Innovations in Transdisciplinary Science, Health Care and Policy. *Frontiers in Dental Medicine*. 2021:82.
3. Hajishengallis G, Chavakis T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities. *Nat Rev Immunol*. 2021;21(7):426-440.
4. Kim J, Amar S. Periodontal disease and systemic conditions: a bidirectional relationship. *Odontology*. 2006;94(1):10-21.
5. Bui FQ, Almeida-da-Silva CLC, Huynh B, et al. Association between periodontal pathogens and systemic disease. *Biomed J*. 2019;42(1):27-35.
6. In: *Oral Health in America: Advances and Challenges: Executive Summary*. Bethesda (MD)2021.
7. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. *Lancet*. 2005;366(9499):1809-1820.
8. Kinane DF, Attstrom R, European Workshop in Periodontology group B. Advances in the pathogenesis of periodontitis. Group B consensus report of the fifth European Workshop in Periodontology. *J Clin Periodontol*. 2005;32 Suppl 6:130-131.
9. Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. *Nat Rev Immunol*. 2015;15(1):30-44.
10. Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases. *Nat Rev Dis Primers*. 2017;3:17038.



11. Kassebaum NJ, Smith AGC, Bernabe E, et al. Global, Regional, and National Prevalence, Incidence, and Disability-Adjusted Life Years for Oral Conditions for 195 Countries, 1990-2015: A Systematic Analysis for the Global Burden of Diseases, Injuries, and Risk Factors. *J Dent Res.* 2017;96(4):380-387.
12. Nazir M, Al-Ansari A, Al-Khalifa K, Alhareky M, Gaffar B, Almas K. Global Prevalence of Periodontal Disease and Lack of Its Surveillance. *ScientificWorldJournal.* 2020;2020:2146160.
13. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet.* 2017;390(10100):1211-1259.
14. Eke PI, Dye BA, Wei L, et al. Update on Prevalence of Periodontitis in Adults in the United States: NHANES 2009 - 2012. *Journal of periodontology.* 2015:1-18.
15. Eke PI, Wei L, Borgnakke WS, et al. Periodontitis prevalence in adults  $\geq$  65 years of age, in the USA. *Periodontol 2000.* 2016;72(1):76-95.
16. Highfield J. Diagnosis and classification of periodontal disease. *Aust Dent J.* 2009;54 Suppl 1:S11-26.
17. Petersen PE, Yamamoto T. Improving the oral health of older people: the approach of the WHO Global Oral Health Programme. *Community Dent Oral Epidemiol.* 2005;33(2):81-92.
18. Hajishengallis G, Lamont RJ. Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. *Mol Oral Microbiol.* 2012;27(6):409-419.

19. Lamont RJ, Hajishengallis G. Polymicrobial synergy and dysbiosis in inflammatory disease. *Trends Mol Med*. 2015;21(3):172-183.
20. Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: dynamic communities and host interactions. *Nat Rev Microbiol*. 2018;16(12):745-759.
21. Tsukasaki M, Komatsu N, Nagashima K, et al. Host defense against oral microbiota by bone-damaging T cells. *Nature communications*. 2018;9(1):701.
22. Socransky SS, Haffajee AD. Periodontal microbial ecology. *Periodontol 2000*. 2005;38:135-187.
23. Holt SC, Ebersole JL. Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the "red complex", a prototype polybacterial pathogenic consortium in periodontitis. *Periodontol 2000*. 2005;38:72-122.
24. Dewhirst FE, Chen T, Izard J, et al. The human oral microbiome. *J Bacteriol*. 2010;192(19):5002-5017.
25. Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. *Nat Rev Microbiol*. 2010;8(7):481-490.
26. Paster BJ, Boches SK, Galvin JL, et al. Bacterial diversity in human subgingival plaque. *J Bacteriol*. 2001;183(12):3770-3783.
27. Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial flora of the oral cavity. *J Clin Microbiol*. 2005;43(11):5721-5732.
28. Curtis MA, Zenobia C, Darveau RP. The relationship of the oral microbiota to periodontal health and disease. *Cell Host Microbe*. 2011;10(4):302-306.
29. Kinane DF, Peterson M, Stathopoulou PG. Environmental and other modifying factors of the periodontal diseases. *Periodontol 2000*. 2006;40:107-119.

30. Genco RJ, Borgnakke WS. Risk factors for periodontal disease. *Periodontol 2000*. 2013;62(1):59-94.
31. Baima G, Romandini M, Citterio F, Romano F, Aimetti M. Periodontitis and Accelerated Biological Aging: A Geroscience Approach. *J Dent Res*. 2022;101(2):125-132.
32. Kwok V, Caton JG. Commentary: prognosis revisited: a system for assigning periodontal prognosis. *Journal of periodontology*. 2007;78(11):2063-2071.
33. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K. Relationship between periodontal infections and systemic disease. *Clin Microbiol Infect*. 2007;13 Suppl 4:3-10.
34. Chapple IL, Genco R, working group 2 of the joint EFPAAPw. Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. *Journal of periodontology*. 2013;84(4 Suppl):S106-112.
35. Tonetti MS, Van Dyke TE, working group 1 of the joint EFPAAPw. Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. *Journal of periodontology*. 2013;84 Suppl 4S:S24-S29.
36. Sanz M, Kornman K, working group 3 of the joint EFPAAPw. Periodontitis and adverse pregnancy outcomes: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. *Journal of periodontology*. 2013;84(4 Suppl):S164-169.
37. Baima G, Muwalla M, Testa G, et al. Periodontitis prevalence and severity in inflammatory bowel disease: A case-control study. *Journal of periodontology*. 2023;94(3):313-322.
38. Brito F, Zaltman C, Carvalho AT, et al. Subgingival microflora in inflammatory bowel disease patients with untreated periodontitis. *Eur J Gastroenterol Hepatol*. 2013;25(2):239-245.

39. Sanz M, Herrera D, Kebschull M, et al. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. *J Clin Periodontol*. 2020;47 Suppl 22(Suppl 22):4-60.
40. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. *J Clin Invest*. 2007;117(3):514-521.
41. North American Society for Pediatric Gastroenterology H, Nutrition, Colitis Foundation of A, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. *J Pediatr Gastroenterol Nutr*. 2007;44(5):653-674.
42. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. *Clin Microbiol Rev*. 2002;15(1):79-94.
43. Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. *Journal of Crohn's and Colitis*. 2013;7(10):827-851.
44. Lockhart-Mummery H, Morson B. Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. *Gut*. 1960;1(2):87-105.
45. Geboes K. Histopathology of Crohn's disease and ulcerative colitis. *Inflammatory bowel disease*. 2003;4:210-228.
46. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. *Lancet*. 2017;389(10080):1756-1770.
47. Bernstein CN, Fried M, Krabshuis J, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. *Inflammatory bowel diseases*. 2010;16(1):112-124.

48. Kornbluth A, Sachar DB, Gastroenterology PPCotACo. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. *Official journal of the American College of Gastroenterology| ACG*. 2010;105(3):501-523.
49. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. *Lancet*. 2012;380(9853):1606-1619.
50. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. *Gastroenterol Hepatol (N Y)*. 2011;7(4):235-241.
51. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. *Gastroenterol Clin North Am*. 2002;31(1):307-327.
52. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. *World J Gastroenterol*. 2006;12(30):4819-4831.
53. Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. *J Crohns Colitis*. 2016;10(3):239-254.
54. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2015;21(8):1982-1992.
55. Zippi M, Corrado C, Pica R, et al. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. *World J Gastroenterol*. 2014;20(46):17463-17467.
56. Lauritano D, Boccalari E, Di Stasio D, et al. Prevalence of Oral Lesions and Correlation with Intestinal Symptoms of Inflammatory Bowel Disease: A Systematic Review. *Diagnostics (Basel)*. 2019;9(3).

57. Greuter T, Bertoldo F, Rechner R, et al. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment. *J Pediatr Gastroenterol Nutr.* 2017;65(2):200-206.
58. Koutsochristou V, Zellos A, Dimakou K, et al. Dental Caries and Periodontal Disease in Children and Adolescents with Inflammatory Bowel Disease: A Case-Control Study. *Inflamm Bowel Dis.* 2015;21(8):1839-1846.
59. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. *J Clin Gastroenterol.* 1996;23(1):29-34.
60. Lankarani KB, Sivandzadeh GR, Hassanpour S. Oral manifestation in inflammatory bowel disease: a review. *World J Gastroenterol.* 2013;19(46):8571-8579.
61. Storwick GS, Prihoda MB, Fulton RJ, Wood WS. Pyodermatitis-pyostomatitis vegetans: a specific marker for inflammatory bowel disease. *J Am Acad Dermatol.* 1994;31(2 Pt 2):336-341.
62. Harty S, Fleming P, Rowland M, et al. A prospective study of the oral manifestations of Crohn's disease. *Clin Gastroenterol Hepatol.* 2005;3(9):886-891.
63. Katz J, Shenkman A, Stavropoulos F, Melzer E. Oral signs and symptoms in relation to disease activity and site of involvement in patients with inflammatory bowel disease. *Oral Dis.* 2003;9(1):34-40.
64. Pittock S, Drumm B, Fleming P, et al. The oral cavity in Crohn's disease. *J Pediatr.* 2001;138(5):767-771.
65. Muhvic-Urek M, Tomac-Stojmenovic M, Mijandrusic-Sincic B. Oral pathology in inflammatory bowel disease. *World J Gastroenterol.* 2016;22(25):5655-5667.

66. Ojha J, Cohen DM, Islam NM, Stewart CM, Katz J, Bhattacharyya I. Gingival involvement in Crohn disease. *J Am Dent Assoc.* 2007;138(12):1574-1581; quiz 1614-1575.
67. Eckel A, Lee D, Deutsch G, Maxin A, Oda D. Oral manifestations as the first presenting sign of Crohn's disease in a pediatric patient. *J Clin Exp Dent.* 2017;9(7):e934-e938.
68. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. *Gut.* 1994;35(11):1590-1592.
69. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. *Gut.* 1994;35(7):950-954.
70. Kuenzig ME, Manuel DG, Donelle J, Benchimol EI. Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease. *CMAJ.* 2020;192(45):E1394-E1402.
71. Faye AS, Colombel JF. Aging and IBD: A New Challenge for Clinicians and Researchers. *Inflamm Bowel Dis.* 2022;28(1):126-132.
72. Kaplan GG. The global burden of IBD: from 2015 to 2025. *Nat Rev Gastroenterol Hepatol.* 2015;12(12):720-727.
73. Collaborators GBDIBD. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol.* 2020;5(1):17-30.
74. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *The Lancet.* 2017;390(10114):2769-2778.

75. Kaplan GG. The global burden of IBD: from 2015 to 2025. *Nature reviews Gastroenterology & hepatology*. 2015;12(12):720-727.
76. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. *Clin Gastroenterol Hepatol*. 2007;5(12):1424-1429.
77. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV, Jr. Incidence and Prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010. *Clin Gastroenterol Hepatol*. 2017;15(6):857-863.
78. Loddo I, Romano C. Inflammatory Bowel Disease: Genetics, Epigenetics, and Pathogenesis. *Front Immunol*. 2015;6:551.
79. de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. *Nat Rev Gastroenterol Hepatol*. 2016;13(1):13-27.
80. Turpin W, Goethel A, Bedrani L, Croitoru M, K. Determinants of IBD Heritability: Genes, Bugs, and More. *Inflamm Bowel Dis*. 2018;24(6):1133-1148.
81. Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. *Gut*. 2013;62(10):1505-1510.
82. Chang JT. Pathophysiology of Inflammatory Bowel Diseases. *The New England journal of medicine*. 2020;383(27):2652-2664.
83. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature*. 2007;448(7152):427-434.
84. Huang H, Fang M, Jostins L, et al. Fine-mapping inflammatory bowel disease loci to single-variant resolution. *Nature*. 2017;547(7662):173-178.



85. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. *Nat Genet.* 1996;14(2):199-202.
86. McGovern DP, Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. *Nat Genet.* 2010;42(4):332-337.
87. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet.* 2011;43(3):246-252.
88. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet.* 2008;40(8):955-962.
89. de Lange KM, Moutsianas L, Lee JC, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. *Nat Genet.* 2017;49(2):256-261.
90. Ye BD, McGovern DP. Genetic variation in IBD: progress, clues to pathogenesis and possible clinical utility. *Expert Rev Clin Immunol.* 2016;12(10):1091-1107.
91. Okamoto D, Kawai Y, Kakuta Y, et al. Genetic Analysis of Ulcerative Colitis in Japanese Individuals Using Population-specific SNP Array. *Inflamm Bowel Dis.* 2020;26(8):1177-1187.
92. Yang SK, Hong M, Zhao W, et al. Genome-wide association study of ulcerative colitis in Koreans suggests extensive overlapping of genetic susceptibility with Caucasians. *Inflamm Bowel Dis.* 2013;19(5):954-966.
93. Chen J, Tian W. Explaining the disease phenotype of intergenic SNP through predicted long range regulation. *Nucleic Acids Res.* 2016;44(18):8641-8654.

94. Ramos PS, Criswell LA, Moser KL, et al. A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap. *PLoS genetics*. 2011;7(12):e1002406.
95. Park SC, Jeon YT. Genetic Studies of Inflammatory Bowel Disease-Focusing on Asian Patients. *Cells*. 2019;8(5).
96. Elding H, Lau W, Swallow DM, Maniatis N. Dissecting the genetics of complex inheritance: linkage disequilibrium mapping provides insight into Crohn disease. *American journal of human genetics*. 2011;89(6):798-805.
97. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature*. 2012;491(7422):119-124.
98. Raychaudhuri S, Plenge RM, Rossin EJ, et al. Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. *PLoS genetics*. 2009;5(6):e1000534.
99. Elding H, Lau W, Swallow DM, Maniatis N. Refinement in localization and identification of gene regions associated with Crohn disease. *American journal of human genetics*. 2013;92(1):107-113.
100. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. *Nat Genet*. 2009;41(7):776-782.
101. Mayberry JF, Judd D, Smart H, Rhodes J, Calcraft B, Morris JS. Crohn's disease in Jewish people--an epidemiological study in south-east Wales. *Digestion*. 1986;35(4):237-240.

102. Ibrahim ML, Klement JD, Lu C, et al. Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis. *Cell Rep.* 2018;25(11):3036-3046 e3036.
103. Zhang K, Hocker JD, Miller M, et al. A single-cell atlas of chromatin accessibility in the human genome. *Cell.* 2021;184(24):5985-6001 e5919.
104. Ouyang X, Zhang R, Yang J, et al. Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation. *Nature communications.* 2011;2:314.
105. Zhang R, Qi CF, Hu Y, et al. T follicular helper cells restricted by IRF8 contribute to T cell-mediated inflammation. *J Autoimmun.* 2019;96:113-122.
106. Yan M, Wang H, Sun J, et al. Cutting Edge: Expression of IRF8 in Gastric Epithelial Cells Confers Protective Innate Immunity against Helicobacter pylori Infection. *Journal of immunology.* 2016;196(5):1999-2003.
107. Li JY, Xiao J, Gao M, et al. IRF/Type I IFN signaling serves as a valuable therapeutic target in the pathogenesis of inflammatory bowel disease. *Int Immunopharmacol.* 2021;92:107350.
108. Thumbigere-Math V, Foster BL, Bachu M, et al. Inactivating Mutation in IRF8 Promotes Osteoclast Transcriptional Programs and Increases Susceptibility to Tooth Root Resorption. *J Bone Miner Res.* 2019;34(6):1155-1168.
109. Chu EY, Deeb JG, Foster BL, Hajishengallis E, Somerman MJ, Thumbigere-Math V. Multiple Idiopathic Cervical Root Resorption: A Challenge for a Transdisciplinary Medical-Dental Team. *Front Dent Med.* 2021;2.

110. Das A, Yesupatham SK, Allison D, et al. Mouse Homolog of Human IRF8<sup>G388S</sup> Mutation Provides Novel Insight into Osteoclastogenesis and Tooth Root Resorption. *bioRxiv*. 2023:2023.2004.2023.537931.
111. Santos MPC, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. *Ann Gastroenterol*. 2018;31(1):14-23.
112. Monsen U, Bernell O, Johansson C, Hellers G. Prevalence of inflammatory bowel disease among relatives of patients with Crohn's disease. *Scand J Gastroenterol*. 1991;26(3):302-306.
113. Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. *World J Gastrointest Pharmacol Ther*. 2016;7(1):51-65.
114. Loftus EV, Jr., Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. *Gut*. 2000;46(3):336-343.
115. Loftus EV, Jr., Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. *Gastroenterology*. 1998;114(6):1161-1168.
116. Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. *J Crohns Colitis*. 2015;9(6):507-515.
117. Burisch J, Pedersen N, Cukovic-Cavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. *Gut*. 2014;63(4):588-597.
118. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. *Gut*. 2014;63(3):423-432.

119. Zheng H, Zhang C, Wang Q, Feng S, Fang Y, Zhang S. The impact of aging on intestinal mucosal immune function and clinical applications. *Front Immunol.* 2022;13:1029948.
120. Sovran B, Hugenholtz F, Elderman M, et al. Age-associated Impairment of the Mucus Barrier Function is Associated with Profound Changes in Microbiota and Immunity. *Sci Rep.* 2019;9(1):1437.
121. Buford TW. (Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease. *Microbiome.* 2017;5(1):80.
122. Roth MP, Petersen GM, McElree C, Feldman E, Rotter JI. Geographic origins of Jewish patients with inflammatory bowel disease. *Gastroenterology.* 1989;97(4):900-904.
123. Aniwaniwan S, Harmsen WS, Tremaine WJ, Loftus EV, Jr. Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010. *Therap Adv Gastroenterol.* 2019;12:1756284819827692.
124. Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly? *World J Gastroenterol.* 2007;13(46):6134-6139.
125. Berkowitz L, Schultz BM, Salazar GA, et al. Impact of Cigarette Smoking on the Gastrointestinal Tract Inflammation: Opposing Effects in Crohn's Disease and Ulcerative Colitis. *Front Immunol.* 2018;9:74.
126. Carter MJ, Lobo AJ, Travis SP, Ibd Section BSoG. Guidelines for the management of inflammatory bowel disease in adults. *Gut.* 2004;53 Suppl 5(Suppl 5):V1-16.
127. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut.* 2019;68(Suppl 3):s1-s106.

128. Neurath MF. Current and emerging therapeutic targets for IBD. *Nat Rev Gastroenterol Hepatol.* 2017;14(5):269-278.
129. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. *Journal of medicine and life.* 2019;12(2):113.
130. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. *Gastroenterology.* 2001;120(3):622-635.
131. Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. *Journal of inflammation research.* 2014:113-120.
132. Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. *World journal of gastroenterology: WJG.* 2009;15(21):2570.
133. Lee D, Albenberg L, Compher C, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. *Gastroenterology.* 2015;148(6):1087-1106.
134. Colitis-Pathophysiology U. Inflammatory bowel disease part I: ulcerative colitis-pathophysiology and conventional and alternative treatment options. *Altern Med Rev.* 2003;8(3):247-283.
135. Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. *Journal of Crohn's and Colitis.* 2017;11(6):649-670.
136. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. *Gut.* 2011;60(5):571-607.

137. Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 2: surgical management and special situations. *Journal of Crohn's and Colitis*. 2017;11(2):135-149.
138. Brito F, de Barros FC, Zaltman C, et al. Prevalence of periodontitis and DMFT index in patients with Crohn's disease and ulcerative colitis. *J Clin Periodontol*. 2008;35(6):555-560.
139. Vavricka SR, Manser CN, Hediger S, et al. Periodontitis and gingivitis in inflammatory bowel disease: a case-control study. *Inflamm Bowel Dis*. 2013;19(13):2768-2777.
140. Katsanos KH, Torres J, Roda G, Brygo A, Delaporte E, Colombel JF. Review article: non-malignant oral manifestations in inflammatory bowel diseases. *Aliment Pharmacol Ther*. 2015;42(1):40-60.
141. Said HS, Suda W, Nakagome S, et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. *DNA Res*. 2014;21(1):15-25.
142. Aleksandra Nielsen A, Nederby Nielsen J, Schmedes A, Brandslund I, Hey H. Saliva Interleukin-6 in patients with inflammatory bowel disease. *Scand J Gastroenterol*. 2005;40(12):1444-1448.
143. Szczeklik K, Owczarek D, Pytko-Polonczyk J, Kesek B, Mach TH. Proinflammatory cytokines in the saliva of patients with active and non-active Crohn's disease. *Pol Arch Med Wewn*. 2012;122(5):200-208.
144. Figueredo CM, Martins AP, Lira-Junior R, et al. Activity of inflammatory bowel disease influences the expression of cytokines in gingival tissue. *Cytokine*. 2017;95:1-6.

145. Damen GM, Hol J, de Ruiter L, et al. Chemokine production by buccal epithelium as a distinctive feature of pediatric Crohn disease. *J Pediatr Gastroenterol Nutr.* 2006;42(2):142-149.
146. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. *The New England journal of medicine.* 2009;361(21):2033-2045.
147. Lin Z, Wang Z, Hegarty JP, et al. Genetic association and epistatic interaction of the interleukin-10 signaling pathway in pediatric inflammatory bowel disease. *World J Gastroenterol.* 2017;23(27):4897-4909.
148. Engelhardt KR, Shah N, Faizura-Yeop I, et al. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. *J Allergy Clin Immunol.* 2013;131(3):825-830.
149. Bachtiar EW, Cornain S, Siregar B, Raharjo TW. Decreased CD4+/CD8+ ratio in major type of recurrent aphthous ulcers: comparing major to minor types of ulcers. *Asian Pac J Allergy Immunol.* 1998;16(2-3):75-79.
150. Schmidt J, Weigert M, Leuschner C, et al. Active matrix metalloproteinase-8 and periodontal bacteria-interlink between periodontitis and inflammatory bowel disease? *Journal of periodontology.* 2018;89(6):699-707.
151. Figueredo CM, Brito F, Barros FC, et al. Expression of cytokines in the gingival crevicular fluid and serum from patients with inflammatory bowel disease and untreated chronic periodontitis. *J Periodontal Res.* 2011;46(1):141-146.



152. Enver A, Ozmeric N, Isler SC, et al. Evaluation of periodontal status and cytokine levels in saliva and gingival crevicular fluid of patients with inflammatory bowel diseases. *Journal of periodontology*. 2022;93(11):1649-1660.
153. Zdravkovic ND, Jovanovic IP, Radosavljevic GD, et al. Potential dual immunomodulatory role of VEGF in ulcerative colitis and colorectal carcinoma. *Int J Med Sci*. 2014;11(9):936-947.
154. Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. *Crit Rev Immunol*. 2012;32(1):23-63.
155. Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. *Gastroenterology*. 1990;98(2):464-469.
156. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. *Gastroenterology*. 1994;107(1):103-108.
157. Hedin CRH, Vavricka SR, Stagg AJ, et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. *J Crohns Colitis*. 2019;13(5):541-554.
158. Petrova G, Ferrante A, Gorski J. Cross-reactivity of T cells and its role in the immune system. *Crit Rev Immunol*. 2012;32(4):349-372.
159. Zhao Q, Elson CO. Adaptive immune education by gut microbiota antigens. *Immunology*. 2018;154(1):28-37.
160. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. *Nat Clin Pract Gastroenterol Hepatol*. 2006;3(7):390-407.

161. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell*. 2014;157(1):121-141.
162. Ficarra G, Baroni G, Massi D. Pyostomatitis vegetans: cellular immune profile and expression of IL-6, IL-8 and TNF-alpha. *Head Neck Pathol*. 2010;4(1):1-9.
163. Asquith P, Thompson RA, Cooke WT. Oral manifestations of Crohn's disease. *Gut*. 1975;16(4):249-254.
164. Tan CX, Brand HS, de Boer NK, Forouzanfar T. Gastrointestinal diseases and their orodental manifestations: Part 1: Crohn's disease. *Br Dent J*. 2016;221(12):794-799.
165. Lira-Junior R, Figueredo CM. Periodontal and inflammatory bowel diseases: Is there evidence of complex pathogenic interactions? *World J Gastroenterol*. 2016;22(35):7963-7972.
166. Abrol N, Compton SM, Graf D, Parashar P, Heo G, Gibson MP. Inflammatory bowel disease and periodontitis: A retrospective chart analysis. *Clin Exp Dent Res*. 2022;8(5):1028-1034.
167. Xun Z, Zhang Q, Xu T, Chen N, Chen F. Dysbiosis and Ecotypes of the Salivary Microbiome Associated With Inflammatory Bowel Diseases and the Assistance in Diagnosis of Diseases Using Oral Bacterial Profiles. *Front Microbiol*. 2018;9:1136.
168. Surna A, Kubilius R, Sakalauskiene J, et al. Lysozyme and microbiota in relation to gingivitis and periodontitis. *Med Sci Monit*. 2009;15(2):CR66-73.
169. Forchielli ML, Walker WA. The role of gut-associated lymphoid tissues and mucosal defence. *Br J Nutr*. 2005;93 Suppl 1:S41-48.
170. Cesta MF. Normal structure, function, and histology of mucosa-associated lymphoid tissue. *Toxicol Pathol*. 2006;34(5):599-608.

171. Hevia A, Milani C, Lopez P, et al. Intestinal dysbiosis associated with systemic lupus erythematosus. *mBio*. 2014;5(5):e01548-01514.
172. Cappello F, Rappa F, Canepa F, et al. Probiotics Can Cure Oral Aphthous-Like Ulcers in Inflammatory Bowel Disease Patients: A Review of the Literature and a Working Hypothesis. *Int J Mol Sci*. 2019;20(20).
173. Dudeney TP. Crohn's disease of the mouth. *Proc R Soc Med*. 1969;62(12):1237.
174. Bottomley WK, Giorgini GL, Julienne CH. Oral extension of regional enteritis (Crohn's disease). Report of a case. *Oral Surg Oral Med Oral Pathol*. 1972;34(3):417-420.
175. Croft CB, Wilkinson AR. Ulceration of the mouth, pharynx, and larynx in Crohn's disease of the intestine. *Br J Surg*. 1972;59(4):249-252.
176. Lamster IB, Rodrick ML, Sonis ST, Falchuk ZM. An analysis of peripheral blood and salivary polymorphonuclear leukocyte function, circulating immune complex levels and oral status in patients with inflammatory bowel disease. *Journal of periodontology*. 1982;53(4):231-238.
177. Van Dyke TE, Dowell VR, Jr., Offenbacher S, Snyder W, Hersh T. Potential role of microorganisms isolated from periodontal lesions in the pathogenesis of inflammatory bowel disease. *Infect Immun*. 1986;53(3):671-677.
178. Flemmig TF, Shanahan F, Miyasaki KT. Prevalence and severity of periodontal disease in patients with inflammatory bowel disease. *J Clin Periodontol*. 1991;18(9):690-697.
179. Grossner-Schreiber B, Fetter T, Hedderich J, Kocher T, Schreiber S, Jepsen S. Prevalence of dental caries and periodontal disease in patients with inflammatory bowel disease: a case-control study. *J Clin Periodontol*. 2006;33(7):478-484.

180. Cotti E, Mezzena S, Schirru E, et al. Healing of Apical Periodontitis in Patients with Inflammatory Bowel Diseases and under Anti-tumor Necrosis Factor Alpha Therapy. *J Endod.* 2018;44(12):1777-1782.
181. Chi YC, Chen JL, Wang LH, et al. Increased risk of periodontitis among patients with Crohn's disease: a population-based matched-cohort study. *Int J Colorectal Dis.* 2018;33(10):1437-1444.
182. Nijakowski K, Rutkowski R, Eder P, Korybalska K, Witowski J, Surdacka A. Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease. *Life (Basel).* 2021;11(12).
183. Peddis N, Musu D, Ideo F, Rossi-Fedele G, Cotti E. Interaction of biologic therapy with apical periodontitis and periodontitis: a systematic review. *Aust Dent J.* 2019;64(2):122-134.
184. Zhang Y, Chen J, Fu H, et al. Exosomes derived from 3D-cultured MSCs improve therapeutic effects in periodontitis and experimental colitis and restore the Th17 cell/Treg balance in inflamed periodontium. *Int J Oral Sci.* 2021;13(1):43.
185. Nasidze I, Li J, Quinque D, Tang K, Stoneking M. Global diversity in the human salivary microbiome. *Genome Res.* 2009;19(4):636-643.
186. Gao L, Xu T, Huang G, Jiang S, Gu Y, Chen F. Oral microbiomes: more and more importance in oral cavity and whole body. *Protein Cell.* 2018;9(5):488-500.
187. Schmidt TS, Hayward MR, Coelho LP, et al. Extensive transmission of microbes along the gastrointestinal tract. *Elife.* 2019;8.
188. Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. *J Prosthet Dent.* 2001;85(2):162-169.

189. Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. *PLoS Biol.* 2016;14(8):e1002533.
190. Okumura R, Takeda K. Roles of intestinal epithelial cells in the maintenance of gut homeostasis. *Exp Mol Med.* 2017;49(5):e338.
191. Johansson ME, Sjovall H, Hansson GC. The gastrointestinal mucus system in health and disease. *Nat Rev Gastroenterol Hepatol.* 2013;10(6):352-361.
192. Kamada N, Chen GY, Inohara N, Nunez G. Control of pathogens and pathobionts by the gut microbiota. *Nat Immunol.* 2013;14(7):685-690.
193. Kitamoto S, Nagao-Kitamoto H, Hein R, Schmidt TM, Kamada N. The Bacterial Connection between the Oral Cavity and the Gut Diseases. *J Dent Res.* 2020;99(9):1021-1029.
194. Zhu H, Hart CA, Sales D, Roberts NB. Bacterial killing in gastric juice--effect of pH and pepsin on Escherichia coli and Helicobacter pylori. *J Med Microbiol.* 2006;55(Pt 9):1265-1270.
195. Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. *Basic Clin Pharmacol Toxicol.* 2005;96(2):94-102.
196. Sohn J, Sun Y, Genco R, Kirkwood K. The Periodontal Microenvironment: a Potential Reservoir for Intestinal Pathobionts in Crohn's Disease. *Current Oral Health Reports.* 2020;7:37-44.
197. Byrd KM, Gulati AS. The "Gum-Gut" Axis in Inflammatory Bowel Diseases: A Hypothesis-Driven Review of Associations and Advances. *Front Immunol.* 2021;12:620124.

198. Read E, Curtis MA, Neves JF. The role of oral bacteria in inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol*. 2021;18(10):731-742.
199. Arimatsu K, Yamada H, Miyazawa H, et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. *Sci Rep*. 2014;4:4828.
200. Kitamoto S, Nagao-Kitamoto H, Jiao Y, et al. The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis. *Cell*. 2020;182(2):447-462 e414.
201. Lorenzo-Pouso AI, Castelo-Baz P, Rodriguez-Zorrilla S, Perez-Sayans M, Vega P. Association between periodontal disease and inflammatory bowel disease: a systematic review and meta-analysis. *Acta Odontol Scand*. 2021;79(5):344-353.
202. Sohn J, Li L, Zhang L, et al. Porphyromonas gingivalis indirectly elicits intestinal inflammation by altering the gut microbiota and disrupting epithelial barrier function through IL9-producing CD4(+) T cells. *Mol Oral Microbiol*. 2021.
203. Chen X, Sun B, Li L, et al. The oral microbiome analysis reveals the similarities and differences between periodontitis and Crohn's disease-associated periodontitis. *FEMS Microbiol Lett*. 2022;369(1).
204. Pelaseyed T, Bergstrom JH, Gustafsson JK, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. *Immunol Rev*. 2014;260(1):8-20.
205. Johansson ME, Hansson GC. Immunological aspects of intestinal mucus and mucins. *Nat Rev Immunol*. 2016;16(10):639-649.
206. De Lisle RC, Borowitz D. The cystic fibrosis intestine. *Cold Spring Harb Perspect Med*. 2013;3(9):a009753.

207. Allen JM, Mackos AR, Jagers RM, et al. Psychological stress disrupts intestinal epithelial cell function and mucosal integrity through microbe and host-directed processes. *Gut Microbes*. 2022;14(1):2035661.
208. Bergstrom KS, Kisoos-Singh V, Gibson DL, et al. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. *PLoS Pathog*. 2010;6(5):e1000902.
209. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. *Nat Rev Mol Cell Biol*. 2001;2(4):285-293.
210. Michielan A, D'Inca R. Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. *Mediators Inflamm*. 2015;2015:628157.
211. Rolhion N, Chassaing B. When pathogenic bacteria meet the intestinal microbiota. *Philos Trans R Soc Lond B Biol Sci*. 2016;371(1707).
212. Sorbara MT, Pamer EG. Correction: Interbacterial mechanisms of colonization resistance and the strategies pathogens use to overcome them. *Mucosal Immunol*. 2019;12(3):840.
213. Rios-Covian D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilan CG, Salazar N. Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health. *Front Microbiol*. 2016;7:185.
214. Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. *Cell Microbiol*. 2014;16(7):1024-1033.
215. Freedberg DE, Toussaint NC, Chen SP, et al. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. *Gastroenterology*. 2015;149(4):883-885 e889.

216. Belstrom D, Fiehn NE, Nielsen CH, et al. Differences in bacterial saliva profile between periodontitis patients and a control cohort. *J Clin Periodontol*. 2014;41(2):104-112.
217. Ismail Y, Mahendran V, Octavia S, et al. Investigation of the enteric pathogenic potential of oral *Campylobacter concisus* strains isolated from patients with inflammatory bowel disease. *PLoS One*. 2012;7(5):e38217.
218. Komiya Y, Shimomura Y, Higurashi T, et al. Patients with colorectal cancer have identical strains of *Fusobacterium nucleatum* in their colorectal cancer and oral cavity. *Gut*. 2019;68(7):1335-1337.
219. Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. *Gut*. 1972;13(4):251-256.
220. Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. *Physiol Rev*. 2014;94(2):329-354.
221. Sigthorsson G, Tibble J, Hayllar J, et al. Intestinal permeability and inflammation in patients on NSAIDs. *Gut*. 1998;43(4):506-511.
222. Rogers MAM, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. *Clin Microbiol Infect*. 2016;22(2):178 e171-178 e179.
223. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. *Cell Host Microbe*. 2014;15(3):382-392.
224. Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. *Science*. 2016;352(6285):565-569.



225. Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. *Gut*. 2016;65(5):740-748.
226. Abed J, Maalouf N, Manson AL, et al. Colon Cancer-Associated *Fusobacterium nucleatum* May Originate From the Oral Cavity and Reach Colon Tumors via the Circulatory System. *Front Cell Infect Microbiol*. 2020;10:400.
227. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol*. 2009;9(5):313-323.
228. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. *Nature*. 2012;489(7415):231-241.
229. Atarashi K, Suda W, Luo C, et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. *Science*. 2017;358(6361):359-365.
230. Caselli E, Fabbri C, D'Accolti M, et al. Defining the oral microbiome by whole-genome sequencing and resistome analysis: the complexity of the healthy picture. *BMC Microbiol*. 2020;20(1):120.
231. Wade WG. The oral microbiome in health and disease. *Pharmacol Res*. 2013;69(1):137-143.
232. Curtis MA, Diaz PI, Van Dyke TE. The role of the microbiota in periodontal disease. *Periodontol 2000*. 2020;83(1):14-25.
233. Escapa IF, Chen T, Huang Y, Gajare P, Dewhirst FE, Lemon KP. New Insights into Human Nostril Microbiome from the Expanded Human Oral Microbiome Database (eHOMD): a Resource for the Microbiome of the Human Aerodigestive Tract. *mSystems*. 2018;3(6).

234. Aleti G, Baker JL, Tang X, et al. Identification of the Bacterial Biosynthetic Gene Clusters of the Oral Microbiome Illuminates the Unexplored Social Language of Bacteria during Health and Disease. *mBio*. 2019;10(2).
235. McLean JS, Bor B, Kerns KA, et al. Acquisition and Adaptation of Ultra-small Parasitic Reduced Genome Bacteria to Mammalian Hosts. *Cell Rep*. 2020;32(3):107939.
236. He X, McLean JS, Edlund A, et al. Cultivation of a human-associated TM7 phylotype reveals a reduced genome and epibiotic parasitic lifestyle. *Proc Natl Acad Sci U S A*. 2015;112(1):244-249.
237. Bor B, Bedree JK, Shi W, McLean JS, He X. Saccharibacteria (TM7) in the Human Oral Microbiome. *J Dent Res*. 2019;98(5):500-509.
238. Hajishengallis G, Liang S, Payne MA, et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. *Cell Host Microbe*. 2011;10(5):497-506.
239. Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. *Nat Rev Microbiol*. 2012;10(10):717-725.
240. Lamont RJ, Jenkinson HF. Subgingival colonization by *Porphyromonas gingivalis*. *Oral Microbiol Immunol*. 2000;15(6):341-349.
241. Lamont RJ, Jenkinson HF. Life below the gum line: pathogenic mechanisms of *Porphyromonas gingivalis*. *Microbiol Mol Biol Rev*. 1998;62(4):1244-1263.
242. Holt SC, Kesavalu L, Walker S, Genco CA. Virulence factors of *Porphyromonas gingivalis*. *Periodontology 2000*. 1999;20(1):168-238.

243. Travis J, Pike R, Imamura T, Potempa J. Porphyromonas gingivalis proteinases as virulence factors in the development of periodontitis. *Journal of periodontal research*. 1997;32(1):120-125.
244. Signat B, Roques C, Poulet P, Duffaut D. Role of Fusobacterium nucleatum in periodontal health and disease. *Current issues in molecular biology*. 2011;13(2):25-36.
245. Settem RP, El-Hassan AT, Honma K, Stafford GP, Sharma A. Fusobacterium nucleatum and Tannerella forsythia induce synergistic alveolar bone loss in a mouse periodontitis model. *Infection and immunity*. 2012;80(7):2436-2443.
246. Zambon JJ. Actinobacillus actinomycetemcomitans in human periodontal disease. *Journal of clinical periodontology*. 1985;12(1):1-20.
247. Slots J, Reynolds HS, Genco RJ. Actinobacillus actinomycetemcomitans in human periodontal disease: a cross-sectional microbiological investigation. *Infection and immunity*. 1980;29(3):1013-1020.
248. Zambon JJ, Christersson LA, Slots J. Actinobacillus actinomycetemcomitans in human periodontal disease: prevalence in patient groups and distribution of biotypes and serotypes within families. *Journal of periodontology*. 1983;54(12):707-711.
249. Fives-Taylor PM, Meyer DH, Mintz KP, Brissette C. Virulence factors of Actinobacillus actinomycetemcomitans. *Periodontology 2000*. 1999;20:136-167.
250. Wilson M, Henderson B. Virulence factors of Actinobacillus actinomycetemcomitans relevant to the pathogenesis of inflammatory periodontal diseases. *FEMS microbiology reviews*. 1995;17(4):365-379.

251. Kolenbrander PE, Andersen RN, Blehert DS, Eglund PG, Foster JS, Palmer RJ, Jr. Communication among oral bacteria. *Microbiol Mol Biol Rev.* 2002;66(3):486-505, table of contents.
252. Kaplan CW, Ma X, Paranjpe A, et al. Fusobacterium nucleatum outer membrane proteins Fap2 and RadD induce cell death in human lymphocytes. *Infect Immun.* 2010;78(11):4773-4778.
253. Han YW, Shi W, Huang GT, et al. Interactions between periodontal bacteria and human oral epithelial cells: Fusobacterium nucleatum adheres to and invades epithelial cells. *Infect Immun.* 2000;68(6):3140-3146.
254. Sharma A. Virulence mechanisms of Tannerella forsythia. *Periodontol 2000.* 2010;54(1):106-116.
255. Sharma A, Inagaki S, Honma K, Sfantescu C, Baker PJ, Evans RT. Tannerella forsythia-induced alveolar bone loss in mice involves leucine-rich-repeat BspA protein. *J Dent Res.* 2005;84(5):462-467.
256. Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. *Physiological reviews.* 2010.
257. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. *Nature.* 2012;489(7415):242-249.
258. Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. *J Allergy Clin Immunol.* 2020;145(1):16-27.
259. Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. *Nature immunology.* 2013;14(7):685-690.

260. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. *science*. 2005;308(5728):1635-1638.
261. Thursby E, Juge N. Introduction to the human gut microbiota. *Biochemical journal*. 2017;474(11):1823-1836.
262. Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes*. 2012;3(1):4-14.
263. Rowland I, Gibson G, Heinken A, et al. Gut microbiota functions: metabolism of nutrients and other food components. *Eur J Nutr*. 2018;57(1):1-24.
264. Meurman JH, Halme L, Laine P, von Smitten K, Lindqvist C. Gingival and dental status, salivary acidogenic bacteria, and yeast counts of patients with active or inactive Crohn's disease. *Oral Surg Oral Med Oral Pathol*. 1994;77(5):465-468.
265. Stein JM, Lammert F, Zimmer V, et al. Clinical periodontal and microbiologic parameters in patients with Crohn's disease with consideration of the CARD15 genotype. *Journal of periodontology*. 2010;81(4):535-545.
266. Man SM, Zhang L, Day AS, Leach ST, Lemberg DA, Mitchell H. *Campylobacter concisus* and other *Campylobacter* species in children with newly diagnosed Crohn's disease. *Inflamm Bowel Dis*. 2010;16(6):1008-1016.
267. Strauss J, Kaplan GG, Beck PL, et al. Invasive potential of gut mucosa-derived *Fusobacterium nucleatum* positively correlates with IBD status of the host. *Inflamm Bowel Dis*. 2011;17(9):1971-1978.
268. Docktor MJ, Paster BJ, Abramowicz S, et al. Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease. *Inflamm Bowel Dis*. 2012;18(5):935-942.

269. Kelsen J, Bittinger K, Pauly-Hubbard H, et al. Alterations of the Subgingival Microbiota in Pediatric Crohn's Disease Studied Longitudinally in Discovery and Validation Cohorts. *Inflamm Bowel Dis*. 2015;21(12):2797-2805.
270. Baima G, Massano A, Squillace E, et al. Shared microbiological and immunological patterns in periodontitis and IBD: A scoping review. *Oral Dis*. 2022;28(4):1029-1041.
271. Hajishengallis G, Chavakis T, Hajishengallis E, Lambris JD. Neutrophil homeostasis and inflammation: novel paradigms from studying periodontitis. *J Leukoc Biol*. 2015;98(4):539-548.
272. Moutsopoulos NM, Konkel J, Sarmadi M, et al. Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. *Sci Transl Med*. 2014;6(229):229ra240.
273. Fournier BM, Parkos CA. The role of neutrophils during intestinal inflammation. *Mucosal Immunol*. 2012;5(4):354-366.
274. Wera O, Lancellotti P, Oury C. The Dual Role of Neutrophils in Inflammatory Bowel Diseases. *J Clin Med*. 2016;5(12).
275. Yucel-Lindberg T, Bage T. Inflammatory mediators in the pathogenesis of periodontitis. *Expert Rev Mol Med*. 2013;15:e7.
276. Sochalska M, Potempa J. Manipulation of Neutrophils by *Porphyromonas gingivalis* in the Development of Periodontitis. *Front Cell Infect Microbiol*. 2017;7:197.
277. Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. *Gut*. 2019;68(9):1688-1700.

278. Zhan C, Zhou Z, Huang Y, et al. Exploration of the shared gene signatures and molecular mechanisms between periodontitis and inflammatory bowel disease: evidence from transcriptome data. *Gastroenterol Rep (Oxf)*. 2023;11:goad041.
279. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. *J Leukoc Biol*. 2007;81(1):28-37.
280. Johnstone KF, Wei Y, Bittner-Eddy PD, et al. Calprotectin (S100A8/A9) Is an Innate Immune Effector in Experimental Periodontitis. *Infect Immun*. 2021;89(10):e0012221.
281. Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. *Gut*. 2021;70(10):1978-1988.
282. Figueredo CM, Nunes JGR, Mello-Neto JM, Carvalho AT, Ipe DS. Higher salivary expression of S100A12 in patients with ulcerative colitis and chronic periodontitis. *Eur J Gastroenterol Hepatol*. 2021;33(1):116-117.
283. Yu S, Ding L, Liang D, Luo L. Porphyromonas gingivalis inhibits M2 activation of macrophages by suppressing alpha-ketoglutarate production in mice. *Mol Oral Microbiol*. 2018;33(5):388-395.
284. Liu L, Liang L, Liang H, et al. Fusobacterium nucleatum Aggravates the Progression of Colitis by Regulating M1 Macrophage Polarization via AKT2 Pathway. *Front Immunol*. 2019;10:1324.
285. Liu H, Hong XL, Sun TT, Huang XW, Wang JL, Xiong H. Fusobacterium nucleatum exacerbates colitis by damaging epithelial barriers and inducing aberrant inflammation. *J Dig Dis*. 2020;21(7):385-398.

286. Lin Y, Yang X, Yue W, et al. Chemerin aggravates DSS-induced colitis by suppressing M2 macrophage polarization. *Cell Mol Immunol*. 2014;11(4):355-366.
287. Kuhl AA, Erben U, Kredel LI, Siegmund B. Diversity of Intestinal Macrophages in Inflammatory Bowel Diseases. *Front Immunol*. 2015;6:613.
288. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. *Nature*. 1998;392(6673):245-252.
289. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. *Science*. 2005;307(5707):254-258.
290. Cutler CW, Jotwani R. Dendritic cells at the oral mucosal interface. *J Dent Res*. 2006;85(8):678-689.
291. Herbert BA, Novince CM, Kirkwood KL. *Aggregatibacter actinomycetemcomitans*, a potent immunoregulator of the periodontal host defense system and alveolar bone homeostasis. *Mol Oral Microbiol*. 2016;31(3):207-227.
292. Jotwani R, Pulendran B, Agrawal S, Cutler CW. Human dendritic cells respond to *Porphyromonas gingivalis* LPS by promoting a Th2 effector response in vitro. *Eur J Immunol*. 2003;33(11):2980-2986.
293. Becker C, Wirtz S, Blessing M, et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. *J Clin Invest*. 2003;112(5):693-706.
294. Stagg AJ, Hart AL, Knight SC, Kamm MA. The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria. *Gut*. 2003;52(10):1522-1529.
295. Moutsopoulos NM, Kling HM, Angelov N, et al. *Porphyromonas gingivalis* promotes Th17 inducing pathways in chronic periodontitis. *J Autoimmun*. 2012;39(4):294-303.



296. Zhao X, Liu J, Zhang C, et al. Porphyromonas gingivalis exacerbates ulcerative colitis via Porphyromonas gingivalis peptidylarginine deiminase. *Int J Oral Sci.* 2021;13(1):31.
297. Jia L, Wu R, Han N, et al. Porphyromonas gingivalis and Lactobacillus rhamnosus GG regulate the Th17/Treg balance in colitis via TLR4 and TLR2. *Clin Transl Immunology.* 2020;9(11):e1213.
298. Menegat JS, Lira-Junior R, Siqueira MA, et al. Cytokine expression in gingival and intestinal tissues of patients with periodontitis and inflammatory bowel disease: An exploratory study. *Arch Oral Biol.* 2016;66:141-146.
299. Champaiboon C, Yongvanitchit K, Pichyangkul S, Mahanonda R. The immune modulation of B-cell responses by Porphyromonas gingivalis and interleukin-10. *Journal of periodontology.* 2000;71(3):468-475.
300. Danielsen AK, Damgaard C, Massarenti L, et al. B-cell cytokine responses to Porphyromonas gingivalis in patients with periodontitis and healthy controls. *Journal of periodontology.* 2023.
301. Noronha AM, Liang Y, Hetzel JT, et al. Hyperactivated B cells in human inflammatory bowel disease. *J Leukoc Biol.* 2009;86(4):1007-1016.
302. Uzzan M, Martin JC, Mesin L, et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. *Nat Med.* 2022;28(4):766-779.
303. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. *Lancet.* 2007;369(9573):1627-1640.
304. Sohn J, Li L, Zhang L, et al. Periodontal disease is associated with increased gut colonization of pathogenic Haemophilus parainfluenzae in patients with Crohn's disease. *Cell Rep.* 2023;42(2):112120.

305. Wang Z, Li S, Tan D, et al. Association between inflammatory bowel disease and periodontitis: A bidirectional two-sample Mendelian randomization study. *J Clin Periodontol.* 2023;50(6):736-743.
306. Bertl K, Burisch J, Pandis N, Bruckmann C, Klinge B, Stavropoulos A. Periodontitis prevalence in patients with ulcerative colitis and Crohn's disease - PPCC: A case-control study. *J Clin Periodontol.* 2022;49(12):1262-1274.
307. Enver A, Ozmeric N, Isler SC, et al. Evaluation of periodontal status and cytokine levels in saliva and gingival crevicular fluid of patients with inflammatory bowel diseases. *Journal of periodontology.* 2022.
308. Imai J, Ichikawa H, Kitamoto S, et al. A potential pathogenic association between periodontal disease and Crohn's disease. *JCI Insight.* 2021;6(23).
309. Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. Dextran sulfate sodium (DSS)-induced colitis in mice. *Curr Protoc Immunol.* 2014;104:15 25 11-15 25 14.
310. Kiesler P, Fuss IJ, Strober W. Experimental Models of Inflammatory Bowel Diseases. *Cell Mol Gastroenterol Hepatol.* 2015;1(2):154-170.
311. Wirtz S, Popp V, Kindermann M, et al. Chemically induced mouse models of acute and chronic intestinal inflammation. *Nat Protoc.* 2017;12(7):1295-1309.
312. Mizoguchi A. Animal models of inflammatory bowel disease. *Prog Mol Biol Transl Sci.* 2012;105:263-320.
313. Qian J, Lu J, Huang Y, et al. Periodontitis Salivary Microbiota Worsens Colitis. *J Dent Res.* 2022;101(5):559-568.


314. Tsuzuno T, Takahashi N, Yamada-Hara M, et al. Ingestion of *Porphyromonas gingivalis* exacerbates colitis via intestinal epithelial barrier disruption in mice. *J Periodontal Res.* 2021;56(2):275-288.
315. Wang X, Luo Y, Huang Y, et al. Periodontitis-induced oral microbiome alterations provide clues on how periodontitis exacerbates colitis. *J Clin Periodontol.* 2023;50(5):627-641.
316. Lin S, Zhang X, Zhu X, et al. *Fusobacterium nucleatum* aggravates ulcerative colitis through promoting gut microbiota dysbiosis and dysmetabolism. *Journal of periodontology.* 2023;94(3):405-418.
317. Oz HS, Ebersole JL. A novel murine model for chronic inflammatory alveolar bone loss. *J Periodontal Res.* 2010;45(1):94-99.
318. Oz HS, Chen T, Ebersole JL. A model for chronic mucosal inflammation in IBD and periodontitis. *Dig Dis Sci.* 2010;55(8):2194-2202.
319. de Mello-Neto JM, Elangovan G, Ervolino E, Johnson NW, Gustafsson A, da Figueredo CM. Colitis induced by dextran sulphate sodium causes histopathological and immunological changes in the periodontal tissues of Wistar rats. *J Periodontal Res.* 2022;57(6):1267-1276.
320. Rautava J, Pinnell LJ, Vong L, Akseer N, Assa A, Sherman PM. Oral microbiome composition changes in mouse models of colitis. *J Gastroenterol Hepatol.* 2015;30(3):521-527.
321. Metzger CE, Narayanan SA, Elizondo JP, et al. DSS-induced colitis produces inflammation-induced bone loss while irisin treatment mitigates the inflammatory state in both gut and bone. *Sci Rep.* 2019;9(1):15144.

322. Hamdani G, Gabet Y, Rachmilewitz D, Karmeli F, Bab I, Dresner-Pollak R. Dextran sodium sulfate-induced colitis causes rapid bone loss in mice. *Bone*. 2008;43(5):945-950.
323. Habashneh RA, Khader YS, Alhumouz MK, Jadallah K, Ajlouni Y. The association between inflammatory bowel disease and periodontitis among Jordanians: a case-control study. *J Periodontal Res*. 2012;47(3):293-298.
324. Yu HC, Chen TP, Chang YC. Inflammatory bowel disease as a risk factor for periodontitis under Taiwanese National Health Insurance Research database. *J Dent Sci*. 2018;13(3):242-247.
325. Zhang L, Gao X, Zhou J, et al. Increased risks of dental caries and periodontal disease in Chinese patients with inflammatory bowel disease. *Int Dent J*. 2020;70(3):227-236.
326. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. *Genome Res*. 2012;22(2):299-306.
327. Dejea CM, Wick EC, Hechenbleikner EM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. *Proc Natl Acad Sci U S A*. 2014;111(51):18321-18326.
328. Drewes JL, White JR, Dejea CM, et al. High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. *NPJ Biofilms Microbiomes*. 2017;3:34.
329. Pascal V, Pozuelo M, Borrueal N, et al. A microbial signature for Crohn's disease. *Gut*. 2017;66(5):813-822.
330. Flemer B, Warren RD, Barrett MP, et al. The oral microbiota in colorectal cancer is distinctive and predictive. *Gut*. 2018;67(8):1454-1463.

331. Schirmer M, Denson L, Vlamakis H, et al. Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. *Cell Host Microbe*. 2018;24(4):600-610 e604.
332. Dinakaran V, Mandape SN, Shuba K, et al. Identification of Specific Oral and Gut Pathogens in Full Thickness Colon of Colitis Patients: Implications for Colon Motility. *Front Microbiol*. 2018;9:3220.
333. Vieira-Silva S, Sabino J, Valles-Colomer M, et al. Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses. *Nat Microbiol*. 2019;4(11):1826-1831.
334. Flemer B, Lynch DB, Brown JM, et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. *Gut*. 2017;66(4):633-643.
335. Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. *J Natl Cancer Inst*. 2013;105(24):1907-1911.
336. Yang Y, Misra BB, Liang L, et al. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer. *Theranostics*. 2019;9(14):4101-4114.
337. Wang X, Jia Y, Wen L, et al. Porphyromonas gingivalis Promotes Colorectal Carcinoma by Activating the Hematopoietic NLRP3 Inflammasome. *Cancer Res*. 2021;81(10):2745-2759.
338. Lee YC, Liu CY, Lee CL, Zhang RH, Huang CJ, Yen TL. The Periodontopathic Pathogen, Porphyromonas gingivalis, Involves a Gut Inflammatory Response and Exacerbates Inflammatory Bowel Disease. *Pathogens*. 2022;11(1).


339. Prasoodanan PKV, Sharma AK, Mahajan S, et al. Western and non-western gut microbiomes reveal new roles of *Prevotella* in carbohydrate metabolism and mouth-gut axis. *NPJ Biofilms Microbiomes*. 2021;7(1):77.
340. Lloyd-Price J, Arze C, Ananthkrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature*. 2019;569(7758):655-662.
341. Kirk KF, Nielsen HL, Thorlacius-Ussing O, Nielsen H. Optimized cultivation of *Campylobacter concisus* from gut mucosal biopsies in inflammatory bowel disease. *Gut Pathog*. 2016;8:27.

**Figure 1**




**Figure 1.** Schematic of *IRF8* gene structure with previously reported IBD single nucleotide polymorphisms (SNPs), genotypic changes, and P values.

**Figure 2**



**Figure 2. One hit, not enough wit – A multi-hit model: (red circle)** The onset of periodontitis leads to expansion of pathogenic oral bacteria. These bacteria can translocate to the intestine, either via ingestion or through the circulatory system. Normally, ingested oral bacteria are inactivated as they pass through the stomach. **(green circle)** Several factors, such as genetic disorders, medications, diet, smoking, alcohol, aging, and stress may disrupt intestinal barrier function and shift the gut microbiota long-term. This disruption can reduce colonization resistance, facilitating the establishment of oral bacteria in the gut. **(blue circle)** Once established in the gut, oral bacteria activate both innate and adaptive immune responses leading to intestinal inflammation. Oral dysbiosis or disrupted gut barrier alone are insufficient to predispose the host to IBD. Both a sufficient load of oral pathogens and disrupted barrier function are necessary for oral pathogens to successfully colonize the gut, which then activates immune responses leading to intestinal inflammation.





**Figure 3. Oral pathogen-mediated immune responses that drive gut inflammation in IBD.** Periodontitis onset triggers expansion of pathogenic oral bacteria. Constant saliva swallowing enables these bacteria to translocate to the gut. A compromised intestinal barrier function, marked by diminished mucus and epithelial barrier integrity, facilitates the penetration of oral bacteria into the sub-epithelial regions. Neutrophils, the first responders, attempt to phagocytose the ingested bacteria and release antimicrobial substances. Additionally, the antigen-presenting cells (APCs) in the gut recognize the microbial invaders through pattern recognition receptors like Toll-like receptors (TLRs). Once activated, these cells release a cocktail of pro-inflammatory molecules: interleukin (IL)-6, IL-12, IL-23, IL-1 $\beta$ , tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), and chemokines. Consequently, these molecules guide the differentiation of naive T helper (Th0) cells into Th1, Th2, Th17, and Treg cells. Furthermore, B cells become activated by recognizing bacterial antigens and differentiate into plasma cells, which produce antibodies specific to the oral bacterial antigens. These antibodies neutralize or opsonize bacteria and can form immune complexes, intensifying inflammation. The concerted actions of innate and adaptive immune cells lead to the initiation or exacerbation of inflammatory process in IBD, highlighting the far-reaching effects of oral bacterial dysbiosis. Figure created with BioRender.com.